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MECHANISTIC STUDIES TO UNDERSTAND THE ROLE OF HUMAN GUT 
MICROBIOTA IN COLONIZATION RESISTANCE AND GUT HEALTH 
SUDEEP GHIMIRE 
2020 
Human gut microbiota is comprised of thousands of species which fall into two major 
categories or “enterotypes” based on dominating bacteria: “Bacteroides” and “Prevotella”. 
Bacteroides enterotype dominates the microbiota of the western population because of a 
high protein and fat diet, whereas Prevotella enterotype is dominate in the gut of the eastern 
population because of a high carbohydrate diet. While most of the microbiota studies 
focused on the Bacteroides enterotype using both metagenomics and culturomics, 
Prevotella enterotype is understudied, especially in the field of culturomics. The structure 
of the Prevotella dominated gut microbiome is revealed by metagenomic studies, but the 
individual bacterial species and their characteristics require culturomics and phenotypic 
characterization studies. To understand how microbes assemble into communities and 
provide colonization resistance against pathogens, we used the culturomics approach to 
capture the bacterial diversity of the Prevotella dominated community. We cultured 1590 
isolates belonging to 102 bacterial species and characterized them for their substrate 
utilization, short chain fatty acid production and inhibition of Clostridium difficile. We 
found that 66 bacterial species were able to inhibit C. difficile in vitro. Furthermore, using 
a combinatorial community assembly approach, we identified the minimum number of 
bacteria required to resist C. difficile in vitro is twelve. During this culturomics, we also 





Furthermore, to understand how the Prevotella dominated community is shaped by certain 
prebiotic substrates, we combined rice bran and quercetin to analyze their effect on 
microbiome composition in minibioreactors. The combination of these prebiotics 
significantly reduces potential pathogenic bacteria by alleviating propionate levels. Also, 
there are studies suggesting inhibition of C. difficile may occur by conversion of bile acids 
by C. scindens. We analyzed the genetic differences of five C. scindens strains and tested 
their ability to inhibit C. difficile in vitro. We found a variation in C. scindens genomes and 
their ability to inhibit C. difficile in the presence and absence of bile. This research 
improves our understanding of gut microbiota using culturomics and identifies 
mechanisms utilized by gut microbes to inhibit C. difficile in vitro, which is valuable step 
in the development of biotherapeutics for gut diseases in future.  
 
Key words: Human gut microbiome, culturomics, colonization resistance, minibioreactor, 





CHAPTER 1: IDENTIFYING CLOSTRIDIOIDES DIFFICILE-INHIBITING GUT 
COMMENSALS USING CULTUROMICS, PHENOTYPING, AND 
COMBINATORIAL COMMUNITY ASSEMBLY   
Sudeep Ghimire a, b, Chayan Roy a, b, Supapit Wongkunaa,b, Linto Antony a, b, Abhijit Maji 
a, b, Mitchel Chan Keena a, Andrew Foley a, and Joy Scaria a, b* 
 
aDepartment of Veterinary and Biomedical Sciences, South Dakota State University, 
Brookings, SD, USA. 















A major function of the gut microbiota is to provide colonization resistance, wherein 
pathogens are inhibited or suppressed below infectious level. However, the fraction of gut 
microbiota required for colonization resistance remains unclear. We used culturomics to 
isolate a gut microbiota culture collection comprising 1590 isolates belonging to 102 
species. Estimated by metagenomic sequencing of fecal samples used for culture, this 
culture collection represents 34.57% of taxonomic diversity and 70% functional capacity. 
Using whole genome sequencing we characterized species representatives from this 
collection, and predicted their phenotypic traits, further characterizing isolates by defining 
nutrient utilization profile and short chain fatty acid (SCFA) production. When screened 
using a co-culture assay, 66 species in our culture collection inhibited C. difficile. Several 
phenotypes, particularly, growth rate, production of SCFAs, and the utilization of mannitol, 
sorbitol or succinate correlated with C. difficile inhibition. We used a combinatorial 
community assembly approach to formulate defined bacterial mixes inhibitory to C. 
difficile. When 256 combinations were tested, we found both species composition and 
blend size to be important in inhibition. Our results show that the interaction of bacteria 
with each other in a mix and with other members of gut commensals must be investigated 










Antibiotic treatment causes instability of gut microbiota and the loss of colonization 
resistance, allowing pathogens such as C. difficile to colonize, causing recurrent infection 
and mortality. Although fecal microbiome transplantation has shown to be an effective 
treatment for C. difficile infection (CDI), a more desirable approach would be the use of a 
defined mix of inhibitory gut bacteria. C. difficile-inhibiting species and bacterial 
combinations we identify herein improve our understanding of the ecological interactions 
controlling colonization resistance against C. difficile and could aid the design of defined 
















Normal functioning of the human gut requires a balanced interaction between our mucosal 
surface, diet, the microbiota, and its metabolic by-products. A major determinant of the gut 
homeostasis is the presence of a healthy, diverse commensal microbiota which prevents 
pathogenic bacteria from colonizing the gut or keeping their number below pathogenic 
levels. This function of the gut microbiome is called colonization resistance (1, 2). 
Perturbations of the gut microbiome referred to as dysbiosis could result in the loss of 
colonization resistance (3). Dysbiosis and loss of gut microbiome colonization resistance 
caused by antibiotics, for example, can predispose people to enteric infections. 
Clostridioides difficile infection (CDI) of the gut following antibiotic treatment is a clear 
demonstration of this phenomenon. Clostridioides difficile is a Gram-positive, spore 
forming anaerobe and is the leading cause of antibiotic induced diarrhea in hospitalized 
patients (4).  
 
Antibiotic treatment of CDI often causes recurrence (5). It has been shown that infusion of 
fecal microbiome from healthy people into CDI patients gut can resolve CDI and prevent 
recurrence (6, 7). This procedure termed as fecal microbiome transplantation (FMT) has 
become a common treatment for CDI (8). However, there has been concerns regarding the 
long-term health consequence of FMT. Recently, there has been reports of weight gain (9) 






The development of defined bacterial mixes from the healthy microbiota, which can 
resolve CDI, poses an alternative to FMT (11). However, the exact number of species 
needed in an efficacious defined bacterial mix for CDI remains unknown, and was 
reportedly in the range of 10–33 species when defined bacteriotherapy was tested in a 
limited number of patients (12, 13). A mix of spore-forming species tested in phase II 
clinical trials, despite its initial success, resulted later in recurrence (14). The use of high-
throughput anaerobic gut bacterial culturing, coupled with sequencing, improves the 
cultivability of the gut microbiota (15-17), facilitating the development of culture 
collections of gut commensals that can be screened for identification of species conferring 
colonization resistance, or an understanding of the ecological interactions stabilizing or 
destabilizing colonization resistance.  
 
Here we report the cultivation, using culturomics, of 1590 gut commensals comprising 102 
species from healthy human donors. We phenotyped and sequenced genomes of the 
representative species in this culture collection. We then screened the strains to identify 
species inhibiting C. difficile. A combinatorial community assembly approach in which 
256 strain combinations were tested to identify the species interactions that improve or 
diminish C. difficile inhibition. Our results show that both species composition and 
interactions are both important determinants of C. difficile inhibition phenotype.   Our 
approach and culture library—besides advancing the understanding of bacterial 
community interactions determining colonization resistance—could prove useful in other 





Materials and Methods 
Fecal sample collection, culture conditions, isolate identification, and genome 
sequencing: We collected fecal samples with the approval of the Institutional Review 
Board (IRB), South Dakota State University. All procedures were performed following 
IRB guidelines. We collected fresh fecal samples from six healthy adult donors from 
Brookings, South Dakota, USA with no antibiotic consumption during the previous year. 
We transferred fecal samples to an anaerobic chamber within 10 minutes of voiding and 
diluted them 10-fold with phosphate-buffered saline, and mixed individual fecal samples 
in equal ratio to make the pooled sample for culturing. We used a modified brain heart 
infusion (mBHI) broth (ingredients listed in Supplementary Text 1) for culture. We used 
chloroform and heat treatment to isolate spore-forming species. We plated the 104 dilution 
of the pooled sample on each of the media conditions described (See supplementary text 
1) in strictly anaerobic conditions. We selected 1590 isolates from all culture conditions 
and identified them using MALDI-ToF (MALDI Biotyper, Bruker Inc) against reference 
spectra (Supplementary Table 1). We identified isolates unidentified at this step using 16S 
rRNA gene sequencing, for which we prepared total genomic DNA using the OMEGA 
E.Z.N.A genomic DNA isolation kit (Omega Bio-tek, GA) according to the manufacturer’s 
protocol. We amplified full length bacterial 16s rDNA using the universal forward (27F) 
and reverse (1492R) primers, respectively, under standard PCR conditions. We sequenced 
the amplified DNA using the Sanger dideoxy method. We trimmed raw sequences 
generated for low-quality regions from either end and constructed consensus sequences 
from multiple primers using Genious (18) with default parameters. Based on full length 





isolates. For bacteria initially identified using MALDI-TOF, we extracted full length 16s 
RNA gene sequences from the genome using Barrnap 
(https://github.com/tseemann/barrnap) for phylogenetic tree creation. The sequences were 
aligned using MUSCLE (19) and evolutionary distances were computed using Jukes-
Cantor method. Finally we created the Neighbor Joining tree with a bootstrap of 1000 
replicates using MEGA6 (20).  
 
To further characterize the strain library, we selected representative isolates from each 
species for whole genome sequencing, extracting genomic DNA from overnight culture of 
the isolates using the OMEGA E.Z.N.A genomic DNA isolation kit (Omega Bio-tek, GA) 
according to the manufacturer’s protocol. We prepared sequencing libraries the Nextera 
XT kit, sequencing them using Illumina 2x 300 paired-end sequencing chemistry on the 
Miseq platform (See Supplementary Text 1). We first filtered the raw reads for quality and 
sequencing adaptors with PRINSEQ (21), and then assembled them de novo using 
Unicycler (22), performing quality check of the assembly results with QUAST (23) and 
Bandage (24) all in default mode. We performed gene calling using Prokka (25) with a 
minimum ORF length of 100 bp.  
 
Characterization of donor fecal samples using shotgun metagenome sequencing: We 
extracted total community DNA from 0.25 g of each donor fecal sample using MoBio 
Powersoil DNA isolation kit according to the manufacturer’s instructions. To enrich 
microbial DNA, using previously published protocol, we depleted host DNA in the isolated 





enriched DNA using the Nextera XT library preparation kit (Illumina inc. San Diego, CA), 
performing sequencing following the protocols used for bacterial genomes described 
above. After quality correction, we removed human host reads using Bowtie2 v.1.1.2(27) 
and performed taxonomy assignment using Kaiju (28) in greedy mode. We searched reads 
against the proGenomes (29) reference database of protein sequences containing a non-
redundant set from more than 25,000 genomes from every species cluster recovered by 
specI (30), using the NCBI non-redundant database for comparative analysis. Thereafter, 
we calculated the Simpson dominance index (D), Shannon Diversity Index (H) and 
Shannon Equitability Index (EH), using an assembly-based approach to characterize the 
donor fecal metagenomes. For this, we assembled reads de novo using default metaSPAdes 
(SPAdes 3.12.0) (31), specifically designed for assembly of complex metagenomic 
communities. For initial assembly, we error corrected reads using spades-hammer with 
default parameters, thereafter checking assembly results with default MetaQUAST v 5.0 
(32). We removed contigs of less than 500 bp from the resultant datasets, and performed 
ORF predictions on the filtered contigs with MetaGeneMark (33) with a minimum length 
cutoff of 100 bp. 
 
Computation of gene repertoire and the functional analysis of isolate genomes and 
donor fecal metagenomes: To determine the gene repertoire in the isolate genomes and 
donor fecal metagenomes, we constructed a non-redundant gene catalog from our total data 
using cd-hit (34, 35) for comparison against the previously published integrated catalog of 
reference genes in the human gut microbiome (36). After gene calling, we clustered the 





overlap. We checked these datasets using BLAT to avoid over-representation in the gene 
catalog. We then compared our gene dataset against the previously mentioned integrated 
catalog (36). For functional mapping, we mapped amino acid sequences from all the 
individual datasets and clustered non-redundant sets against the EggNOG database v3.0 
(37).  
 
For gaining a better insight into the putative and hypothetical population genomes present 
within the donor fecal samples, but not isolated using the culturomics approach, population 
genome bin creation is considered superior to taxonomy assignment of the raw reads. We 
therefore constructed population genome bins from the metagenomes using MaxBin2with 
acceptance criteria of 90% completeness and < 5% redundancy, mapping back raw reads 
on the assembled contigs using Bowtie2 (38) for coverage information. We further 
analyzed all high-confidence bins with specI (30) for species cluster determination. To 
determine the abundance of isolated species from the pooled donor fecal samples, we 
measured the coverage by read mapping with Bowtie2 (38) at 95% identity level. For the 
functional analysis, we performed KEGG annotation for the ORFs obtained from the 
pooled donor fecal metagenome and the isolate genomes. We searched data from all 
comparisons for KO modules using GhostKOALA (39), and performed hierarchical 
clustering of the datasets to generate heat maps with R (http://www.R-project.org/). We 
used Traitar (40) under default parameters to predict 67 phenotypes from the whole 






Phenotypic characterization of the isolated strains: To correlate the genomic features 
with phenotypes, we further characterized the strains for which genomes were sequenced 
by determining the following phenotypic properties: 
 
Carbon source utilization: We determined the ability to utilize 95 carbon sources using 
Biolog Biolog AN MicroPlateTM. Briefly, we grew strains on mBHI plates anaerobically 
for 24 h–48 h at 370C. We used a sterile cotton swab to scrape cells from the plates and 
suspended them in AN inoculating fluid (OD650 < 0.02), using 100 µl of this suspension to 
inoculate AN MicroPlateTM in duplicate, and incubated them at 370C anaerobically. We 
took OD650 readings at 0 h and 48 h post-inoculation and normalized the results for growth 
against water and 0-h OD650 values. 
 
Production of SCFA: To analyze the SCFAs produced by isolates, we grew strains in mBHI 
for 24 hours in anaerobic conditions and added 800 µl of the bacterial culture to 160 µl of 
freshly prepared 25% (w/v) m- phosphoric acid, and froze them at −800C. We thawed 
samples and centrifuged them (>20,000×g) for 30 min. We used 600 µl supernatant for 
injection into the TRACE1310 GC system (ThermoScientific, USA) for SCFA analysis. 
 
Identification of C. difficile-inhibiting strains: We used a co-culture assay in which 
pathogen and test strains were cultured together at a ratio of 1:9 to identify C. difficile-
inhibiting strains in our library, using only those strains reaching OD600  of 1.5 after 24 h 
of growth in mBHI; 82 species met this criterion. We used C. difficile strain R20291 as the 





in mBHI medium anaerobically at 370C and adjusted the OD600 to 0.5. The pathogen and 
the test were mixed together at a ratio of 9:1 and incubated for 18 hours anaerobically at 
370C. We then plated 10−5 & 10−6 dilutions onto C. difficile selective agar, using 
monoculture of C. difficile R20291 as a positive control. We compared colony forming 
units (CFUs) enumerated from co-culture plates against the C. difficile R20291 control. In 
identifying C. difficile-inhibitors in healthy and CDI patients, we calculated the frequency 
of 16 top C. difficile-inhibitors in our collection by metagenome read mapping from a 
previously published dataset (41). 
 
Sequence data Availability: All metagenomic datasets from this project has been 
deposited in NCBI SRA under the bioproject PRJNA494584. Raw whole genome 
sequence data for all the isolates has been deposited under the BioProject PRJNA494608. 
 
Results 
Single medium based culturomics retrieves high species diversity from donor fecal 
samples: In this study, we used metagenome sequencing to characterize the fecal 
microbiome composition of healthy human donors and culturomics to develop a strain 
library to identify C. difficile inhibiting species. As a first step, donor’s fecal samples were 
characterized using shotgun metagenome sequencing.  To this end, fecal samples from six 
donors were sequenced individually and also after pooling in equal proportion. We used 







Figure 1: Gut microbiome composition of donor’s fecal samples. A. Variations in the 
Simpson Dominance (D), Shannon Diversity (H) and Shannon Equitability (EH) indices 
calculated based on the raw reads taxonomic affiliations for individual fecal samples (S1–
S6) and pooled fecal sample (S7). B. Phylum level distribution of bacteria for individual 
fecal samples (S1–S6) and pooled fecal sample (S7). We calculated relative abundance 
values as compared to the total identifiable reads from any dataset. C. Species-level 
distribution of the pooled donor fecal sample (S7). We performed taxonomic classification 





samples constituted 48.9 Gb of data. To determine the diversity of the samples, Simpson 
dominance index (D), Shannon diversity index (H) and Shannon equitability index (EH) 
were calculated for individual samples as well the pooled material. This statistical analysis 
(Hutcheson t-test, p > 0.1) revealed that all donor samples were similar in diversity indices 
and pooling the samples in equal proportion maintained the overall population structure of 
the individual samples (Figure 1A). The donors in this study were recent migrants to the 
United States from Asia and were expected to have a high proportion of Prevotella 
(Prevotella enterotype) in the gut microbiome. Consistent with this expectation, taxonomic 
diversity of the samples in phylum level (Figure 1B) showed the dominance of 
Bacteriodetes while the most abundant genus was Prevotella (Figure 1C).  
 
Using culturomics, we developed a strain library from the pooled fecal samples. Previous 
studies have prevalently used assorted media to isolate gut bacteria (15). For mechanistic 
studies to understand the microbial community interaction, strains need to be pooled in a 
single nutrient medium. While the approach of using different media conditions is useful 
in retrieving high diversity, strains isolated in various media conditions may not be able to 
grow in a single media. This would prevent the use of a culture library in community 
assembly studied in a universal medium. To avoid this problem, we used a modified Brain 
Heart Infusion (mBHI) as the base medium for culturing. We isolated several strains from 
nine species from the mBHI medium. We reasoned that if the species that were growing 
fast in the mBHI medium is suppressed, additional species diversity could be isolated using 
the same medium. We therefore supplemented mBHI with different combinations of 





chloroform treatment to select for spore-forming species. We used 12 conditions for 
culturing (Supplementary Text 1), selecting 1590 colonies from these conditions. We 
determined strain species identity using MALDI-ToF, and 16S rRNA sequencing 
(Supplementary Table 1). We thus isolated 93 more species from the same sample, 
increasing the total diversity in our strain library to 102 species (Figure 2). In Figure 3A, 
we present the frequency of each species isolated in each culture condition. We further 
examined whether our approach could isolate high- and low-abundance species from the 
sample. We therefore sequenced the genome of one representative isolate from each 
species in our library (Supplementary Table 2), mapping the metagenome reads 
(Supplementary Table 3) against the individual species genomes. We mapped 37,669,789 
reads obtained from the pooled sample to species whole genomes (Figure 3B), matching 
19,109,642 reads—34.57% of the total metagenomic diversity—to the metagenomic reads. 
Our single medium-based culturomics method was able to isolate about 34.57% of the 
pooled culture sample diversity. We mapped about 20% reads against the Prevotella copri 
SG-1727 genome isolated from six different conditions—unsurprising, as the fecal donors 
belonged to the Prevotella enterotype. However, we isolated low-abundance species such 
as Olsenella umbonata, for which only 0.5% reads were mapped, in eight different 
conditions (Figure 3B). We isolated both low- and high abundance species with our 
technique and used metagenome binning to estimate the number of species missed by our 
method. Matching metagenome bins against cultured species genomes, we found 50 
matching culture isolates and 33 bins matching none, indicating that our method failed to 






Figure 2: Neighbor-Joining tree of the full length 16S rRNA gene sequences of 102 
cultured species isolated from the pooled donor fecal sample. We computed the 
evolutionary distances using the Jukes-Cantor method, presented in the units of the number 
of base substitutions per site in MEGA6. Symbols and colors represent four different 
bacterial phyla, as referred to the legend. We have highlighted putative novel species (n = 







Figure 3: Efficiency of species 
retrieval in the culture conditions 
tested.  A. Frequency of isolation of 102 
species recovered. B. Prevalence of 
individual species as found from read 







Single medium based culturomics retrieves most frequent gut bacteria in human 
populations and increases gene repertoire in the integrated gene catalog of the gut 
microbiome: The availability of high-quality metagenome data from many human samples 
facilitates the identification of frequently present gut bacterial species in healthy 
populations. A recent study defined 71 bacteria present across 2144 human fecal 
metagenomes (42). To quantify the number of these present in our culture library, we 
matched the whole genomes of 102 bacterial species and 33 metagenome bins against these 
71 frequent species (42), finding our culture library contained 65 of these most frequent 
bacteria (Supplementary Table 4). To determine the relationship between the gene 
repertoire in our culture library and the integrated gene catalog (IGC) of the human 
microbiome, we compared the two datasets. For the comparison against IGC, a non-
redundant gut microbiome gene set of 9.879 million genes generated using 1,267 human 
gut metagenomes from Europe, America and China (36), we generated a non-redundant 
gene set from our cultured genomes and the sample metagenome used for culturing. We 
created 984,515 open reading frames (ORFs) from sample metagenomes and 285,672 
ORFs from cultured species genomes (Supplementary Figure 1A and Supplementary Table 
3) and mapped them against the IGC. Of 285,672 ORFs obtained from cultured genomes, 
we matched 208,708 ORFs (73.05%) to the IGC, while 572,437 ORFs (58.14%) of 984,515 
ORFs obtained from the sample metagenome matched the IGC (Supplementary Figure 1B 
and 1C). In other words, the IGC lacked 26.94% of the ORFs from the cultured isolates 
and 41.85% of the ORFs from the sample metagenome. This shows the potential for 
expansion of the IGC if more Prevotella enterotype donor fecal samples, such as those 






Supplementary Figure 1: A. Numbers of open reading frames (ORFs) found in this 
study in genomes and metagenomes and its comparison with IGC. A. Numbers of non-
redundant ORFs predicted in 102 cultured species and donor fecal metagenomes. We 
generated the number of non-redundant ORFs at 95% identity cutoff for donor 
metagenomes and 102 isolates. B. Comparison of the non-redundant ORFs generated form 
102 cultured species with the existing integrated human gene catalog (IGC). C. 











genomes identifies genes otherwise missing in metagenome sequencing because of low 
depth or assembly issues.  
 
A large number of species in the culture library inhibits C. difficile in vitro: A healthy 
microbiota suppresses pathogen growth in the gut. To identify C. difficile-inhibiting 
species in our culture library, we screened it against C. difficile using a co-culture assay. 
Slow-growing strains would be outcompeted by C. difficile. We therefore used 82 
moderately- or fast-growing species in the co-culture assay. When tested, 66 species 
inhibited C. difficile to varying degrees (Figure 4). In this screen, Bifidobacterium 
adolescentis strain SG-742 was the most efficient inhibitor. Furthermore, all Bifidobacteria 
inhibited C. difficile, signifying their importance in colonization resistance to this 
pathogen. The Lachnospiraceae family were major inhibitors. In a surprising result, 16 
species in our co-culture assay increased the growth of C. difficile (Figure 4), a finding of 
clinical significance, in that a high abundance of these species may confer a higher risk of 
CDI.  
 
Most inhibitors are acetate or butyrate producers: Gut bacteria metabolize diverse 
substrates to produce short chain fatty acids (SCFAs) in the gut (43, 44). SCFAs—
particularly butyrate—act as gut epithelial immune modulators, energy sources for host 
intestinal cells, and pathogen-inhibitors (45, 46). To determine the relationship between 
SCFAs produced and C. difficile inhibition, we estimated the SCFAs produced by all 
species used in the co-culture assay (Figure 5). Our results show that the strains produce 







Figure 4: Inhibition of C. difficile by individual species in vitro. C. difficile CFU counts 
for every individual co-culture assay performed for 82 test species in triplicate. Error bars 
represent standard deviations of the three independent experiments for each inhibition 
assay for individual species. “Green,” “yellow” and “gray” bars represent CFU counts of 







Figure 5: Short chain fatty acid (SCFA) produced by cultured species. A. SCFA 
production by 82 species used for inhibition assay against C. difficile. We measured 
acetate, propionate, isobutyrate, butyrate, isovalerate and valerate using gas 
chromatography, expressed in mM concentration. The figure represents mean SCFA 
measurements from duplicate samples. Color scale bar: “white”: no SCFAs production; 
“dark”: ≥5 mM SCFA production. B. acetate, C. butyrate, D. propionate and E. isovalerate 
production in three major phyla from 80 bacteria when oriented according to phyla 
(Kruskal–Wallis tests, p<0.05). SCFAs levels for two members of Proteobacteria phyla are 





using the non-parametric Kruskal–Wallis test, we found Actinobacteria and Bacteroidetes 
to yield the most acetate (Figure 5B). Firmicutes produced significantly higher butyrate 
than Bacteroidetes (Figure 5C). Other SCFA production did not differ significantly (Figure 
5D & 5E). The majority of high acetate- or butyrate producers were C. difficile-inhibitors. 
 
Relationship between nutrient utilization, C. difficile inhibition and species prevalence 
in patient populations: Commensal species suppress pathogens in the gut chiefly by 
competing for nutrients (47-49). The Biolog AN MicroPlate™ test panel provides a 
standardized method to identify the utilization of 95 nutrient sources by anaerobes. 
Investigating the relationship between nutrient utilization and pathogen inhibition, we 
determined the nutrient utilization of all species in our library. C. difficile is known to 
exploit mannitol, sorbitol or succinate to invade and produce infection in the human gut 
(50, 51). Consistent with this observation, we found 27 C. difficile-inhibitors that utilized 
all three nutrients as carbon sources (Figure 6).  We hypothesized that if the C. difficile-
inhibitors we identified were active in C. difficile suppression in vivo, their abundance 
would be reduced in the gut during antibiotic treatment and CDI. Hence, we determined 
the abundance of the top 16 (top 25%) C. difficile-inhibitors in our library from a study of 
healthy and CDI patient gut microbiomes (41). We determined the frequency of the top 16 
C. difficile-inhibiting isolates in the following groups of human gut metagenomes; (a) CDI 
patients, (b) antibiotic-exposed but no CDI patients, and (C) no antibiotic exposure and no 
CDI (healthy) people. Consistent with our hypothesis, the top 16 C. difficile-inhibitors in 
our screen constituted about 20% of total abundance in the heathy microbiome but were in 






Figure 6: Utilization of 95 nutrient sources by the cultured species. The heatmap 
represents two independent substrate utilization tests normalized against control. Columns 
and rows represent nutrients and strains respectively. We considered growth of ≥ 20% in 
any substrate as compared to the control as positive. “Blue,” “white” and “red” represent 
low, medium and high utilization of the carbon source, respectively. Top row shows 
nutrient utilization of C. difficile. All other strains are arranged in descending order of 
nutrient utilization similarity when compared to C. difficile. We used nearest neighbor 
clustering based on the Pearson correlation to identify nutrient utilization similarity of other 






Figure 7: Frequency of the top 25% C. difficile inhibitors obtained in this study in the 
gut microbiome of C. difficile infected (CDI) and non-CDI patients. AB+ and AB- 
represent samples from non-C. difficile infected patients treated with antibiotics and non-
C. difficile infected patients without antibiotic treatment, respectively. A. The combined 
abundance of top 25% CD-inhibitors (n = 16) from this study in CDI, AB+, and AB- 
metagenomes. B. Individual abundance of the same 16 strains in CDI, AB+, and AB- 













Supplementary Figure 2: Hierarchical 
clustering of KEGG modules from fecal 
sample metagenome, all the 102 species 
(All_isolates), and subsets that were 
found to inhibit C. difficile R20291 
(CD_inhibitors). We annotated 
predicted ORFs from the pooled donor 
fecal metagenome and consortium of 
cultures for KO modules by searching 
against the KEGG database using 
Ghostkoala. We indicate the 
completeness of the KEGG modules by 
the color gradient where we refer to a 
complete module by “0” and the absence 






Interestingly, Prevotella copri (SG-1727)—among the most abundant species in the donor 
samples—was among the species depleted during antibiotic treatment and CDI (Figure 
7B).  
 
Analysis of genotype–phenotype relationships: To identify other phenotypes not covered 
in our phenotype assays and to link phenotype with genotype, we used Traitar (52) to 
predict 67 phenotypes from the genomes of all species in our library. The substrate 
utilization phenotypes based on the Traitar prediction mostly matched the Biolog 
phenotypes (Figure 8A, Supplemental table 6). The first two clusters (green and red, lower 
Figure 8A) comprised mostly the pathogen-inhibitors tested here. The defining traits in 
these clusters related to sugar hydrolysis, mostly matching the Biolog phenotype data. The 
other two clusters (sky blue and mixed) comprised mostly pathogenic species and slow 
growers. Notable traits for pathogen clusters were catalase activity, beta hemolysis activity, 
growth in glycerol and high osmo-tolerance (Figure 8A). To further differentiate these 
traits, we performed principal component analysis (PCA) on the Traitar data. The PCA plot 
(Figure 8B) revealed four distinct clusters (C. difficile-inhibitors, -non-inhibitors, 
pathogens, and slow-growing strains) that explained 67.1% total variance in the first two 
principal components. Slow-growing strains clustered furthest from C. difficile-
inhibitors—logically for any colonization-resistant bacteria, as a fast growth rate would 
more likely outcompete the pathogen. 
 
To understand the genomic basis of colonization-resistant and pathogen-inhibiting strain 
genomes, we used KEGG modules—characteristic gene sets that can be linked to specific 






Figure 8: Prediction of phenotypes from the genomes of the 102 species in the culture 
library. A. Clustering of 102 species based on 67 traits predicted using the Traitar package. 
Each column represents one of 67 traits whereas rows represent 102 species from this 
study. The color scheme of the columns further depicts 11 phenotypic properties from 
proteolysis to enzyme production. B. PCA using the combined predicted traits from Pfam 
annotation. X- and Y-axes show Principal Component 1 & 2, explaining 57.5% and 9.6% 
of the total variance, respectively. Prediction ellipses are based on 0.95 confidences. Color 





in the sample metagenome and 476 modules in the strain genomes. 432 modules were 
common between our sample metagenome and our strain genomes, demonstrating our 
ability to retrieve 77.28% of the metabolic functional capacity of the fecal microbiome 
using our culture method. 82 modules unrecovered in our isolated species comprised 
pathways related to environmental information processing, several components of cell 
signaling, DNA replication and repair pathways, lipid metabolism, RNA and protein 
processing, and the ubiquitin system (Supplementary Figure 2). We then tried to identify 
differences in KEGG modules associated with pathogen-inhibiting and -non-inhibiting 
strain genomes, finding 26 modules present in C. difficile-inhibitors were absent in non-C. 
difficile-inhibitors. Some important modules absent in non-inhibiting species genomes 
were M00698 (multidrug resistance efflux pump BpeEF-OprC), M00332 (Type III 
secretion system), M00438 (Nitrate/nitrite transport system), and M00551 (Benzoate 
degradation). Further work is necessary to understand how these functional modules relate 
to colonization resistance. 
 
Design of defined mix of C. difficile-inhibitors: While single strain vs pathogen co-
culture assay is informative in identifying pathogen inhibiting strains, the inhibition 
patterns are likely to change when inhibiting species interact as a community. These 
communities may express emergent properties difficult to predict from the individual 
members (52). After defining the isolate phenotypes, we used a combinatorial assembly of 
bacteria from our culture collection to design a tractable mix of C. difficile-inhibiting 
isolates. In the first set of experiments, we mixed 15 inhibiting species in equal proportion 







Figure 9: C. difficile inhibition efficiency of the consortia A. Combinations starting with 
15 species pool B. Combinations starting with 12 species pool C. Combinations starting 
with 10 species pool. “Green,” “blue” and “gray” bars represent the parent blend, blend 
with one bacterial species removed at a time and blend with two bacterial species removed 
at a time, respectively. “Red” line represents C. difficile control growth. We normalized 
the growth of C. difficile in each consortium to control C. difficile growth, so as to obtain 
relative C. difficile growth (represented as % C. difficile growth) in each consortium 
condition. We performed each experiment in triplicate, and error bars represent the 








Table 1 describes the overall properties of these isolates, selected based on the criteria of 
the medium pH not dropping below 5.6 after 24 h growth, and representation of overall 
taxonomic diversity at the family level. Investigating how changes in the mix composition 
could affect the inhibition capacity, we removed one or two species at a time from the mix 
of 15 species to create additional mixes, thus testing 121 mixes listed in Supplementary 
Table 8 against C. difficile in co-culture assay format. As shown in Figure 9, the removal 
of strains from the 15-species mix had both positive and negative effects. When we 
removed species, several mixes were less effective than the 15-species mix, and the 
removal of two species increased the inhibition efficiency in a species dependent manner. 
Out of 121 mixes tested, mix number 22, comprising the species listed in Supplementary 
Table 7, most effectively inhibited C. difficile growth (by 79.41%). This clearly 
demonstrates the dependence of inhibition efficiency on the species composition of the 
defined mix used in the co-culture assay. Seeking the minimum number of species 
necessary for an effective C. difficile-inhibiting mix, we performed another set of 
experiments in which either one or two species at a time were removed from the parent 
mix of 12 species. In this round, we tested 79 bacterial mixes comprising species listed in 
Supplementary Table 8 in the co-culture assay. As shown in Figure 9, removal of species 
mostly reduced inhibition efficiency when compared with the parent blend. Again, the 
efficiency was dependent on the species composition of the mix. We performed a third set 
of experiments to determine mixes comprising under ten species that would impact C. 
difficile inhibition efficiency. Removal of species from the 10-species parent set 
diminished inhibition efficiency overall; however, some mixes increased the growth of C. 





of C. difficile growth by these set mixes clearly demonstrates that individual strain 
phenotype can be overridden by species community interactions. In this case, a set of C. 
difficile-inhibitory species, when mixed in a particular combination, increased C. difficile 
growth. Overall, our results demonstrate that new phenotypes masking the individual strain 
phenotype could emerge when microbial consortia are formed, and this emergent property 




We developed a gut commensal culture collection from healthy human donors and 
identified C. difficile-colonization-resistant strains. As human gut microbiome composition 
varies across populations, donor selection for culture is an important consideration. 
Depending on the proportion of Bacteriodes and Prevotella, the human gut microbiome 
has been classified into enterotypes (53). The Asian and African populations—two-thirds 
of the human population fall into the Prevotella enterotype. (54). Information about the 
colonization-conferring species in Prevotella-dominant gut microbiomes is limited; we 
therefore chose recent Asian immigrants in the US as the fecal donors in this study. For 
culture, we used a pooled sample from six donors before culturing, which could have 
positive and negative consequences. Pooling can save substantial time and resources. For 
instance, after pooling we analyzed 1590 colonies; were this to be done individually, the 
number of analyzed colonies would have been 9540. Pooling, however, may distort the 
microbiome composition of individual samples, creating artificial population assemblages 





fecal donors of similar gut microbiome composition could be more useful than that from 
many different people. The publicly available gut microbiota culture collection from the 
human microbiome project is isolated from 265 people (56). Other similar culture 
collections are also isolated from at least over 100 donors (15, 17). Although such 
collections are useful as reference strains, since the donors may have different microbiome 
compositions, the strains isolated may not form stable ecologies if mixed together. In 
contrast, our collection, from a limited number of donors having similar microbiome 
composition, may form a stable ecology when mixed, and could be more useful for studies 
to understand underlying interactions determining colonization resistance and other traits. 
 
Two general approaches have been used previously for developing gut microbiota culture 
collections: the use of culturing samples in several—often up to 64—different nutrient 
media conditions, to isolate diversity (15, 57, 58); or the use of a single medium, needing 
less time and resource but retrieving fewer species (59). In understanding the types of 
bacterial communities responsible for suppressing pathogen growth in the gut, the 
assemblage of simple to complex bacterial communities from cultured strain libraries and 
testing of such consortia against pathogens is commonly performed. Although the use of 
different nutrient media is highly efficient in isolating the maximum number of species 
from gut samples, strains so isolated may not grow in a common nutrient medium, 
diminishing the utility of the strains in community assembly studies. We therefore used a 
single medium-based approach using mBHI for culturing of the fecal bacteria. As shown 
in Figures 2 and 3, we isolated 102 species—representing about 34.57% species diversity 





(Supplementary Figure 1)—comparable to other single medium-based approaches (59-61). 
Furthermore, results in Supplementary Table 3 and Supplementary Figure 2 shows that the 
34.57% diversity isolated represents over 70% functional capacity of the donor gut 
microbiome. According to the insurance hypothesis of microbiota function, more than one 
species performing the same function is recruited in an ecosystem to allow for functional 
redundancy (62, 63), possibly explaining the recovery of 70% function from 34.57% 
species diversity in our library.  
 
Many strains in our culture collection shown in Figures 4 inhibit C. difficile at varying 
levels. Several phenotypes—particularly, growth rate, production of SCFAs, and the 
utilization of mannitol, sorbitol or succinate—correlated with the C. difficile-inhibitor 
phenotype, consistent with previous reports that restoration of depleted SCFAs in the gut 
resolved CDI (64, 65) and competition between C. difficile and commensals for nutrients 
and increased availability of mannitol, sorbitol or succinate allowed C. difficile invasion of 
the gut (50, 51). Top inhibiting species in our collection were also depleted in the CDI 
patient gut, indicating their role in providing colonization resistance against C. difficile 
(Figure 7). The formation of many different defined bacterial mixes using these inhibitory 
strains may improve the inhibition capacity of the individual strains. Overall, we tested 256 
defined mixes using the combinatorial community assembly approach. The combinatorial 
community assembly method presented in Figure 9 shows two important parameters 
defining the efficacy of the defined mixes—the number and type of species in the mix. 
Reducing the number of species in the mix from 15 to 12, did not diminish the overall 





those mixes increased, rather than inhibiting, C. difficile growth. Clearly, adding too many 
species in a mix does not improve inhibition. The threshold of peak efficacy is 12 species 
in the conditions we tested. Our results also underline how, when species are pooled in a 
sub-optimal ecology, undesirable traits could emerge; strains in combination could produce 
new phenotypes not observed individually. Previous work to identify a defined mix of C. 
difficile-inhibiting bacteria also identified varying mix numbers. For instance, more than 
20 years ago, Tvede and Rask-Madsen showed that infusion of a 10-bacterial mix into a 
patient’s colon could resolve CDI (12). Another study in a small patient population found 
treatment with a 33-bacterial mix could alleviate CDI. In a mouse model, Clostridium 
scindens was a more efficient C. difficile-inhibitor when mixed with a defined pool of other 
commensal bacteria (66). Likewise, a mix of six phylogenetically diverse bacteria 
alleviated CDI in a mouse model (67). The complexity of the gut microbiota and its 
variations across populations make the design of defined bacterial C. difficile-inhibiting 
mix not simply a matter of mixing large numbers of diverse species. Since our results show 
that the C. difficile-inhibiting phenotype changes substantially depending on the microbial 
interaction, design of a defined bacterial mix requires a deeper understanding of how 




Overall, we demonstrated that a high percentage of the cultivable fraction of gut microbiota 
from healthy human donors are C. difficile-inhibitors in vitro. Defined bacterial mixes can 





of the mix, new phenotypes could emerge. For instance, a mix of bacteria, rather than 
inhibiting, can increase the growth of C. difficile. In designing defined C. difficile-
inhibiting bacterial mixes in vivo, the interaction of bacteria with each other in a mix and 
with other members of gut commensals demands investigation. The approach of 
combinatorial testing of strains with well-defined phenotypes used in the present study is 
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An anaerobic isolate SG772 belonging to the genus Blautia was isolated from healthy 
human fecal sample. When compared using 16s rRNA sequence identity, SG772 showed 
only 94.46% similarity with its neighbor species B. stercoris. Since strain SG772 showed 
both phenotypic and genomic differences with other members of the type species within 
the genus Blautia, we propose the designation of SG772 as novel species “Blautia 
brookingsii SG772T”.  
 


















The human gut microbiome of European and North American population is typically 
dominated by Bacteroides while Prevotella dominates Asian and African populations(1). 
To determine the cultivable microbial diversity of the Prevotella dominant human gut 
microbiota, fecal samples were cultured from six healthy donors using a high-throughput 
culturomics approach(2). A new species of a bacterium belonging to the genus Blautia was 
isolated during this study. We characterized this strain using the recently proposed taxono-
genomics strategy which utilizes the combination of phenotypic and genomic 
characterization of the strain to define new species. Herein, we describe strain Blautia 
brookingsii SG772T (DSM 107275=CCOS 1888) that was isolated from the healthy human 
gut microbiota. 
 
Materials and Methods, Results and Discussion 
Isolation and growth conditions 
The strain was isolated on a Brain Heart Infusion (BHI) agar medium after 48 hours of 
incubation at 37oC in strict anaerobic condition (85% nitrogen, 10% carbon-dioxide, 5% 
hydrogen). The strain grew in the pH range of 5.5-7.5 with optimum growth at 6.8.  No 
growth of was observed after 20 min of thermal shock at 80oC suggesting its non-spore 








The colonies grown in agar plates appeared to be round, whitish, convex and smooth after 
48 hours of anaerobic incubation on BHI plate. Cells were gram-positive and coccobacillus 
in shape with no flagellum suggesting non-motile nature. Overnight culture of the strain 
SG772T in the broth was centrifuged at 10,000×g. The supernatant was then removed to 
obtain the pellet which was mixed with 30% glycerol solution and frozen to -800C and sent 
to BGSU Center for Microscopy (Bowling Green, OH) for scanning electron microscopy. 
The size of the bacterium under scanning electron microscopy was between 0.5-0.8 x 1.8-
2.5 µm (Figure. 1).  
 
Using API ZYM strip, enzymatic activities were determined. Positive enzymatic reactions 
were observed for esterase (C4), esterase lipase (C8), leucine arylamidase, acid 
phosphatase, -galactosidase, -galactosidase, -glucosidase and N-acetyl--
glucosaminidase. Carbon source utilization of the strain SG772T was determined using 
BIOLOG AN plate. The strain SG772T was grown as lawn in BHI plate for 48 hours and 
the cells were scooped using sterile cotton swab to mix in BIOLOG AN fluid until the 
OD600 reached 0.01. 100 µl of the mixture was pipetted into 96 wells of the BIOLOG AN 
plate and incubated for 24 hours. The initial and final OD were measured and compared to 
control. Those wells with OD growth >20% compared to control were considered as 
growth. Thus, this test revealed that the strain utilized 21 substrates with maximum 
preference for propionic acid followed by L-alanyl-L-glutamine (Table 1). Furthermore, it 





















Figure 2: Phylogenetic tree highlighting the position of strain SG772T with regard to 
other closely related species. The consensus phylogenetic tree showing the was 
constructed using 16S rRNA gene sequences from strain SG772T and its top 30 neighbors 
obtained from EzTaxon.  The evolutionary history was inferred using Neighbor-Joining 
method using Kimura 2-paramter method. The numbers at the nodes indicate bootstrap 
values expressed as percentages of 1000 replications in MEGA X. Clostridium butyricum 






organic acids such as -ketovaleric acid, urocanic acid, glycoxylic acid, fumaric acid, 
galacturonic acid and -hydroxybutyric acid. Comparison of the substrate utilization of 
strain SG772T with other neighbor Blautia strains are given in Table 1. Additionally, 
cellular morphology and optimum pH for growth varied among the different species (Table 
1). Antibiotic sensitivity test using disk diffusion technique displayed that the strain 
SG772T was resistant to tetracycline and streptomycin. However, it was susceptible to 
chloramphenicol, ampicillin, erythromycin, and novobiocin. 
 
Strain Identification 
After initial isolation of the strain SG772T, MALDI-TOF was performed resulting no 
identification (score < 1.7). Therefore, DNA of the strain was isolated and 16S rRNA gene 
was amplified and sequenced using Applied Biosystems 3500xL, Genetic analyser 
(Applied Biosystems, MA, USA). The 16S rRNA sequences were trimmed and assembled 
using Genious 10.2.3 (NJ, US). A continuous stretch of 1440 bp of the 16S rRNA gene of 
strain SG772T was obtained and searched against EzTaxon- e-server (3) for identification. 
This comparison showed that the closest neighbor for strain SG772T is B. stercoris GAM6-
1 sharing only 94.46% sequence similarity (Figure 2).  
 
Genome sequencing and comparison  
The genomic DNA was isolated using E.Z.N.A DNA isolation kit (Omega, Biotek) 






Figure 3: Average Nucleotide Identity (ANI) comparison of Blautia brookingsii 
strain SG772T sp. nov., with other closely related species with standing 









(Illumina Inc, CA), 2×250 paired end chemistry. The reads were assembled using SPAdes 
3.9.0 (4) and the contigs were validated using Quast (5).  
 
Assembly of the strain SG772T genome produced 52 contigs with the genome size of 
3,411,519 bps (N50 = 156,020) and 44.07% GC content. The largest contig was 401,555 
bps while the smallest was of 610 bps. The genome contains 57 tRNA genes, 1 rRNA gene 
and 3061 coding sequences. Additionally, for SG772T genome, the open reading frames 
(ORF) were predicted using Prodigal 2.6 (6) in Prokka software package (7). Transfer RNA 
genes were predicted using Aragorn 1.2 (8) and rRNA genes were annotated using Barrnap 
0.7 (https://github.com/tseemann/barrnap). The comparison of SG772T genome with its 
close species revealed several differences in genome size, G+C content and RNA copies. 
The closely related species of the strain SG772T for which the genomes were available 
NCBI were obtained and the degree of similarity was estimated using OrthoANI software 
(9). For the closest neighbors (Fig 2), OrthoANI values ranged from 69.13 to 73.15%.  The 
type strain SG772T was observed to be close to Blautia wexlerae DSM19850 with 73.15% 
genomic identity while B. schinkii DSM10518 was the farthest (Figure. 3).  
 
Conclusion 
As the sequence identity of the phylogenetically closest validated species is < 98.7 %: the 
threshold recommended to define a species as per nomenclature (10), we propose the strain 





neut., adj., brookingsii, based on the acronym of the Brookings city where the type strain 
was first isolated). The 16S rRNA gene sequence of SG772T is deposited in GenBank under 
accession number MH127966.1. Whole genome sequences are deposited in GenBank 
under BioProject PRJNA436995. Strain SG772T was deposited in the DSMZ-German 
Collection of Microorganisms and Cell Cultures GmbH under DSM 107275 and Culture 





















Table 1: Physiological and substrate utilization characteristics of strain SG772T 
compared with its phylogenetic neighbors.  
(Refer to Ghimire et al., 2020. Genome sequence and description of Blautia brookingsii 
SG772 sp. nov., a novel bacterial species isolated from human faeces, New Microbes New 
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Diet is one of the prominent determinants of gut microbiota composition significantly 
impacting human health. Recent studies with dietary supplements such as rice bran and 
quercetin have been shown to provide a beneficial impact on the host by positively 
influencing the gut microbiota. However, the specific bacterial species impacted when rice 
bran or quercetin is present in the diet is not well understood. Therefore, in this study, we 
used a minibioreactor array system as a model to determine the effect of quercetin and rice 
bran individually, as well as in combination, on gut microbiota without the confounding 
host factors. We found that rice bran exerts higher shift in gut microbiome composition 
when compared to quercetin. At the species level, Acidaminococcus intestini was the only 
significantly enriched taxa when quercetin was supplemented, while 15 species were 
enriched in rice bran supplementation and 13 were enriched when quercetin and rice bran 
were supplemented in combination. When comparing the short chain fatty acid production, 
quercetin supplementation significantly enriched isobutyrate production while propionate 
dominated the quercetin and rice bran combined group. Higher levels of propionate were 
highly correlated to the lower abundance of the potentially pathogenic Enterobacteriaceae 
family. These findings suggest that the combination of rice bran and quercetin serve to 
enrich beneficial bacteria and reduce potential opportunistic pathogens. However, further 
in vivo studies are necessary to determine the synergistic effect of rice bran and quercetin 








Rice bran and quercetin are dietary components that shape host health by interacting with 
the gut microbiome. Both these substrates have been reported to provide nutritional and 
immunological benefits individually. However, considering the complexity of the human 
diet, it is useful to determine how the combination of food ingredients such as rice bran 
and quercetin influences the human gut microbiota. Our study provides insights into how 
these ingredients influence microbiome composition alone and in combination in vitro. 
This will allow us to identify which species in the gut microbiome are responsible for 
biotransformation of these dietary ingredients. Such information is helpful for the 















Gut microbiome influences health and disease (1-3) and is highly affected by diet (4-6). 
Some dietary components are known to enhance host health by promoting the growth of 
beneficial bacteria in the gut, termed as “prebiotics” (7, 8). Quercetin and rice bran have 
been used as prebiotics in mice and pig experiments, showing significant improvements to 
the gut microbiota (9-11). Rice bran, a byproduct of the rice milling process, is available, 
affordable, sustainable, and a globally produced source of prebiotics. It is known to 
supplement nutrients (12), increase beneficial bacteria growth, enhance gut mucosal 
immunity (10), and prevent diseases (9, 13-15). Similarly, quercetin (3,3′,4′,5,7-
pentahydroxyflavone) represents an important subgroup of flavonoids found in fruits and 
leafy vegetables (16). Quercetin has received substantial attention in the past few years 
from the scientific community for exerting anti-inflammatory effects (17, 18) and its 
potential health-promoting properties in the treatment or prevention of cardiovascular 
diseases (19), lung and colorectal cancers (20, 21), and colitis (11, 22).  Furthermore, the 
mammalian body can endure high levels of quercetin without any significant adverse health 
effects (23). 
Despite multiple studies corroborating the beneficial effect of quercetin and rice bran on 
the host, their effect on microbiota varies significantly from study to study and has lower 
taxonomic resolution (22, 24-26). Inter-individual variation in in vivo studies are often due 
to multiple host-related factors which makes it difficult to interpret microbiome results 
(27). In contrast, studying the effect of dietary ingredients on the microbiome in the 
absence of confounding host factors can help to better understand the complex microbial 





shape microbiomes (28). The use of bioreactors allows precise control of the environmental 
conditions that affect microbiome composition which provide increased reproducibility 
and reveal microbial interactions in a more defined way. Minibioreactor array is an in vitro 
anaerobic model system that simulates hindgut conditions for growth of complex, stable 
microbiota without interference of host factors (29). Furthermore, this system helps to 
identify microbial biotransformations and allows for measuring metabolites produced (30). 
We used minibioreactor array systems to gain deeper understanding of how the microbiota 
responds to quercetin and/or rice bran without host interference, and hypothesized that the 
combination of quercetin and rice bran will have a synergistic positive effect on the gut 
microbiota and microbiota metabolism. We observed that the quercetin and rice bran 
combination in the minibioreactors were effective to significantly reduce 
Enterobacteriaceae family members and resulted in higher propionate production. This 
study provides novel insights to species-level shifts in the human gut microbiome in the 






Materials and Methods 
Donor samples, mini-bioreactor array preparation and sample collection: We obtained 
fresh fecal samples from six healthy donors with no prior history of antibiotic consumption 
in the past year. The pooled fecal sample from six individuals was used as the inoculum as 
our prior study showed that pooled sample represented the individual microbial 
composition (31). 
 
The modified BHI medium (31) was used as a control medium. Heat-stabilized rice bran 
(RBT 300) was purchased from Rice Bran Technologies (Sacramento, CA, USA), and the 
extract was prepared as described previously (14) and then added to the control medium 
(final concentration: 2 mg/mL): designated as RB. Quercetin was added to the media at a 
final concentration of 75 mg/L and is referred to as QC. The final experimental group 
consisted of modified BHI medium with the additions of quercetin (75 mg/L) and rice bran 
extract (2 mg/mL) and is identified as QC+RB. Mini-bioreactors (MBRAs) were sterilized, 
assembled and the experiment was performed as described previously (32) with minor 
modifications. Briefly, the input and output on Watson Marlow pumps were set at 1 rpm 
and 2 rpm respectively. The rotating magnetic stirrer was set at 130 rpm. The media 
(Control, QC, RB, and QC+RB) (Figure 1A) were allowed to flow continuously for 24 
hours each in triplicate. Three hundred microliters of the inoculum was introduced into all 
wells with a retention time of 16 hours. The continuous flow model was operated up to 21 
days post-inoculation (Figure 1B). Five hundred microliters of the media was collected for 







Figure 1: Overview of the study design: A) A schematic diagram shown the design of 
four different media conditions used in this study. Single substrates (quercetin or rice bran) 
or the mixture of quercetin and rice bran were used at the final concentration of 75 mg/L 
and 2 mg/mL as shown above in the base medium BHI (see Methods section). Final pH of 
the media was adjusted to 6.8±0.2 for all conditions. Each condition was run in triplicate 
and were inoculated with the same fecal inoculum (see Methods section). B) Outline of the 
bioreactor experiment showing time points for fecal inoculation and sample collection for 








samples for short chain fatty acid (SCFAs) determination were collected at days 4, 7, 14 
and 21 post-inoculation with dietary treatments and controls (Figure 1B).  
 
Microbial DNA extraction and sequencing: DNA isolation was performed on 50 samples 
including duplicate inoculum samples. The DNA was extracted from 500 µl of the sample 
using a Powersoil DNA isolation kit (MoBio Laboratories Inc, CA) following the 
manufacturer’s instructions. After extraction, the quality of DNA was measured using 
NanoDropTM one (Thermo Fisher Scientific, DE) and quantified using Qubit Fluorometer 
3.0 (Invitrogen, CA). The DNA samples were stored at -20oC until further use. To analyze 
the variation of the microbial composition over time, all samples were amplicon sequenced 
using an Illumina MiSeq platform with paired-end V3 chemistry.  The library was prepared 
using an Illumina Nextera XT library preparation kit (Illumina Inc, CA) targeting V3-V4 
regions of the 16S rRNA. The libraries were bead normalized and multiplexed before 
loading into the sequencer. We also performed shotgun metagenome sequencing on twelve 
samples obtained from day 21 to identify species level taxonomical differences between 
the experimental groups. We used the Nextera XT kit (Illumina, San Diego, CA) for the 
preparation of the shotgun metagenome sequencing library. The library was then 
sequenced using paired end 300 base sequencing chemistry using a MiSeq platform.  
 
Data analysis: The time-series changes in the microbial communities were analyzed using 
16S rRNA community analysis in Quantitative Insights into Microbial Ecology framework 





using q2-demux plugin and denoised applying DADA2 (34). All amplicon sequence 
variants were aligned with mafft (35) to construct a phylogeny with fasttree2 (36). The 
outputs rooted-tree.qza, table.qza, taxonomy.qza were then imported into R (37) for 
analysis using phyloseq (38). Shannon diversity and bray curtis dissimilarity indices were 
calculated as alpha and beta diversity metrices. Kruskal-Wallis test at p=0.05 was 
performed to compare the species richness between the groups. The reads were normalized 
by rarefying to 30,000 and the taxonomy was assigned to amplicon sequence variants using 
the q2-feature-classifier (39) using Greengenes as the reference (40). Rarefying the reads 
to 30,000 were enough to estimate total diversity and taxonomy (Supplementary Figure 
1A). Initially, a total of 947 amplicon variants were identified from 50 samples. The 
average number of non-chimeric reads per sample obtained in Qiime2 pipeline was 
92,512±27,631 (mean ± SD). The amplicon sequence variants obtained were filtered to 
select those which are present in at least 20% of samples with a count of 10 each or 
amplicon sequence variants with > 0.001% of total median count reducing the total number 
to 581.  
 
For shotgun metagenomes, raw fastq sequences were quality controlled using Fastqc 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and host reads were 
removed using metaWRAP pipeline (41). Filtered reads were analyzed for taxonomy using 
Kaiju (42) against the proGenomes database (43) using default parameters. The percentage 
abundance of each taxon was plotted using Explicit v2.10.5 (44). The samples from day 21 
yielded a total of 39,332,649 reads of which 70. 86% were classified to 161 different 





bacteria or unassigned to non-viral species, respectively. In addition, the raw counts 
obtained for each taxon were used for calculation of alpha and beta diversity using the 
phyloseq package in R. For identification of differentially abundant taxa in QC, RB and 
QC+RB compared to control medium, the raw counts of abundance of each taxon was then 
Log10(x+1) transformed and fed to DESEq2 (45) package in R. Bacterial taxa which 
significantly altered from the control were further filtered out with the criteria of at least 
log2foldchange (Log2FC) of ≥ 2 and padj value > 0.05. The enriched taxa were selectively 
analyzed for their co-relation to SCFAs phenotypic data using Spearman correlation 
method in R. 
Estimation of Short Chain Fatty Acids (SCFAs): For the estimation of SCFAs, 800 µl of 
samples were collected from each mini-bioreactor, mixed with 160 µl of 25% m-
phosphoric acid and frozen at -80°C until further analysis.  Later, the frozen samples were 
thawed and centrifuged (>15,000 × g) for 20 min. Five hundred microliters of supernatant 
was collected in the tubes before loading into the gas chromatography- mass spectrometry 
(GC-MS) (Agilent Technologies, USA) for analysis (31). The SCFA concentrations were 
compared between the groups using the Kruskal-Wallis test followed by the Dunn test with 










Rice bran produced larger shift in microbiota composition when compared to 
quercetin 
The microbial community richness indicated by the Shannon diversity index showed 
significant differences in the early days (days 4 and 7) due to addition of rice bran in the 
media whether alone or in combination with quercetin (Supplementary Figure 1B). No 
significant changes in the richness was observed among the groups on day 14 and day 21, 
suggesting the stabilization of the microbial communities by day 14. Also, on day 21, 
shotgun metagenome analysis showed no differences in the richness between the four 
conditions (Figure 2B). In contrast, marked differences between the communities were 
evident as early as day 4 by beta diversity analysis (Supplementary Figure 2A). Rice bran 
supplementation showed a greater shift in the bacterial community as shown on days 7, 14 
and 21 (Supplementary Figure 2B, 2C, 2D). Based on Bray-Curtis distance, RB and 
QC+RB treatments were similar to one another and clustered separately from control and 
QC. This supports that there was a limited shift in the community following addition of 
quercetin when compared to rice bran (Supplementary Figure 2). Shotgun metagenome 
sequencing at day 21 also indicated significant differences in the community profile, 
primarily influenced by the addition of rice bran extract in the medium (Figure 2C). 
 
When examined taxonomically, the baseline inoculum composition was dominated by 
Prevotellaceae (29.9±0.87%), followed by Ruminococcaceae (18.82±0.81%) and 






Supplementary Figure 1: Exploratory analysis of predicted taxa and alpha diversity 
of microbiota in quercetin and rice bran: control, QC, RB and QC+RB medium and 
inoculum obtained using 16S rRNA community analysis A) Rarefaction curves 
measuring the bacterial diversity in fecal communities. The curves are based on V3-V4 
16S rRNA gene sequences obtained from a total of 48 samples (12 each from control, QC, 
RB, and QC+RB) from day 4, 7, 14 and 21 and duplicate inoculums  B) Alpha diversity of 







Supplementary Figure 2:  Beta diversity assessment of the microbiota communities 
formed at days 4, 7, 14 and 21 among four groups of media condition (Control, QC, 
RB and QC+RB) determined using 16S rRNA sequence analysis.  The communities 
were ordinated using the “MDS” method followed by Bray-Curtis distance calculation to 
visualize the difference between the groups. Statistically, PERMANOVA using adonis was 
calculated on the beta diversity with p=0.004. The upper panel represents the beta diversity 








Figure 2: Gut microbiota compositional changes following quercetin and rice bran 
supplementation A) Temporal family-level composition of the most abundant 12 bacterial 
taxa at day 4, 7, 14 and 21 and inoculum determined using 16S rRNA community profiling 
for Control, QC, RB and QC+RB conditions. B) Alpha diversity measure (Shannon 
diversity) between Control, supplemented with QC, supplemented with RB and 
supplemented with QC+RB determined using shotgun metagenome sequence analysis at 
day 21. Kruskal-Wallis test was performed for the Shannon diversity indices obtained for 
the groups (p=0.27). C) Beta diversity among the control, QC, RB and QC+RB groups 
were obtained using shotgun metagenome sequence analysis on day 21. “MDS” ordination 
followed by Bray-Curtis distance calculation was used to visualize the differences between 





inoculum (0.33±0.097%). However, the abundance of Prevotellaceae was reduced to ~ 0.0 
% after 21 days in all treatment groups suggesting that not all taxa in the inoculum were 
supported for growth. Over time, there was a major shift in the composition of the 
microbiota between the groups starting as early as day 4 (Figure 2A). The control and 
quercetin medium were dominated by Enterobacteriaceae, followed by Lachnospiraceae 
at day 4. However, by day 21, Lachnospiraceae dominated the control and QC conditions 
followed by Bacteroidaceae. The abundance of Enterobacteriaceae was reduced from 
34.16±1.92 % and 33.26±1.11% on day 4 to 17.62±4.2% and 18.53±3.88% in control and 
QC medium respectively by day 21 (Figure 2A, 2B). Even though ~50% reduction of 
abundance of Enterobacteriaceae was observed for both control and QC medium at day 
21 compared to day 4, the population of Enterobacteriaceae tend to stabilize. However, 
Enterobacteriaceae were highly reduced in both RB and QC+RB conditions. In RB 
medium, Enterobacteriaceae was only reached to 10.212±2.14% at day 4 which further 
reduced to 6.33±2.59% by day 21. At day 21, Veillonellaceae and Lachnospiraceae 
dominanted the RB medium. Similarly, the dominant family were Lachnospiraceae, 
Veillonellaceae and Bacteroidaceae in the quercetin and rice bran combination (QC+RB) 
on day 21. Strikingly, on day 21, the abundance of Enterobacteriaceae was reduced by 
~18.22% to 4.20±3.16% compared to day 4 on QC+RB condition. At day 21, when mean 
abundance of Enterobacteriaceae was compared between control, QC, RB and QC+RB, 
significant reduction was observed in RB and QC+RB (Kruskal-Wallis, p=0.0064).  
 
On day 21, we performed shotgun metagenome analysis to identify the species level 





significantly altered in QC+RB medium. The combination (QC+RB) enriched 13 
additional species and reduced 13 others when the cut off value of Log2FC≥ 2 and padj 
value > 0.05 was applied (Supplementary Table 1). Specifically, members of 
Enterobacteriaceae, Escherichia sp. TW09308, E. coli, E. albertii, Citrobacter koseri, and 
C. youngae were reduced. The Citrobacter species, including C. rodentium, were also 
reduced in RB medium; however, Escherichia species were not significantly reduced in 
this medium.  
 
Further, 13 species were altered significantly in the quercetin group (Supplementary Figure 
3A), and 70 species in the rice bran group compared to control (Supplementary Figure 3B). 
With a cut off Log2FC≥ 2 and padj value > 0.05, Acidaminococcus intestine was the only 
enriched taxa in media supplemented with quercetin while Coprococcus catus, Dorea 
longicatena, Anaerostipes caccae, Eubacterium limosum and Enterococcus faecalis were 
highly reduced. Interestingly, the population of Flavonifractor plautii, a flavonoid 
metabolizing bacterium (46, 47) was significantly reduced in quercetin supplementation. 
Rice bran supplementation alone enriched 15 species, including six different species from 
Veillonella (Supplementary Table 1). 
 
Quercetin and rice bran combination yield higher propionate levels and reduces 
members of Enterobacteriaceae family 
Along with the changes in the taxonomy of the microbial community, diet alters the 





Figure 3: Impact of quercetin (QC) and rice bran (RB) supplementation on bacterial 
taxonomy. Species-wise variation of the most abundant (top 25) of the bacterial taxa 
determined by shotgun metagenome sequencing at day 21 (endpoint) for control, QC, RB 








Figure 4: Impact of quercetin and rice bran (QC+RB) supplementation on bacterial 
species that are significantly altered in QC+RB when compared to the control 
medium. The differential significance of the species was calculated by using DESEq2 (See 
Supplementary Table 1) from shotgun metagenome sequence analysis at day 21. The left 
column represents bacterial species-level taxa while the colors indicate their corresponding 
phyla (“Blue” =Firmicutes, “Brown” =Bacteroidetes, “Pink” =Proteobacteria, “Orange” 






Supplementary Figure 3: Impact of quercetin and rice bran (QC, RB) 
supplementation on bacterial species that are significantly altered in A) QC and B) 
RB when compared to the control medium. The endpoint (day21) shotgun metagenome 
sequence analysis was performed and the differential significance of the species was 
calculated by using DESEq2 (See Supplementary Table 1). The left column represents 
bacterial species-level taxa while the colors indicate their corresponding phyla (“Blue” 
=Firmicutes, “Brown” =Bacteroidetes, “Pink” =Proteobacteria, “Orange” 






altered the fermentation potential of the microbiota, we measured SCFAs from each 
minibioreactor on days 4, 7, 14 and 21. We observed that the amount of each SCFA 
produced was stable by day 14 and at the endpoint, with marked differences between the 
groups (Figure 5A, 5B, 5C, 5D, 5E). At day 21, communities formed in the control and RB 
weighted strongly towards acetate and butyrate production respectively (Supplementary 
Figure 4). Statistically at day 21, acetate production in QC+RB group (48.01±3.3 mM) was 
significantly different from the RB group (33.33±2.44 mM) (Figure 5F). The butyrate 
production in the RB medium was higher but not significantly different compared to the 
other groups (Figures 5H). Similarly, the medium supplemented with quercetin and rice 
bran (QC+RB) weighted towards the production of propionate and butyrate 
(Supplementary Figure 4). Rice bran alone and combined quercetin and rice bran 
supplementation significantly raised propionate levels by at least 3 folds compared to the 
QC group alone (Figure 5G). In contrast, QC supplementation in the medium, weighted 
towards the production of minor SCFAs, i.e. valerate, isovalerate and isobutyrate. 
However, only isobutyrate production was significantly higher in QC compared to QC+RB 
group (Figure 5I). 
 
SCFAs production by microbiota has been associated with pathogen inhibition to benefit 
the host (50). Physiological levels of SCFAs are reported to reduce Enterobacteriaceae 
members by pH mediated action (51). Specifically, propionate production by a propionate 
producing consortium has been shown to reduce antibiotic induced dysbiosis (52). In this 
study, as higher production of propionate weighted towards QC+RB medium at day 21, we 








Supplementary Figure 4: Biplot showing ordination of short-chain fatty acid 
production and bacterial communities formed at day 21 in control, QC, RB and 
QC+RB conditions. Abundances of the bacterial communities at day 21 determined by 








Figure 5: Effect of quercetin (QC) and rice bran (RB) on short Chain Fatty Acids 
(SCFAs) production in QC, RB, and QC+RB compared to control medium in 
minibioreactors. A-E represent the periodic variation of acetate, propionate, butyrate, 
isobutyrate and isovalerate at day 0, 4, 7, 14 and 21 respectively. F-J represent the 
comparison of concentrations of acetate, propionate, butyrate, isobutyrate and isovalerate 
respectively from control, QC, RB and QC+RB medium at day 21 (endpoint). Kruskal-
Wallis test was performed between the groups and posthoc (Dunn test) analysis was 
performed to identify the different significant groups. “*” represents significance at 0.05. 







Figure 6: Spearman correlation of Enterobacteriaceae family members (Citrobacter 
and Escherichia species) log10 abundances at day 21 determined by shotgun 
metagenomics sequence analysis to levels of propionate in the medium. A negative 
correlation is expressed by negative values of correlation coefficient “rho” (ρ) with 










Enterobacteriaceae to propionate levels. Significant high negative correlations were 
observed between the abundance of the members of Enterobacteriaceae family and 
propionate with media change (Figure 6). Citrobacter rodentium (ρ= -0.734, p= 0.009), C. 
koseri (ρ= -0.769, p=0.0052), C. youngae (ρ= -0.776, p= 0.0046), Escherichia albertii (ρ= 
-0.762, p= 0.0058), E. coli (ρ= -0.762, p= 0.00587) and Escherichia sp. TW09308 (ρ= -
0.755, p= 0.0065) (Figure 6A, B, C, D, E, F) were greatly reduced in QC+RB medium, 
whereas propionate levels were at least 3 fold and 1.5 fold higher compared to QC and 
control medium .  
 
Discussion 
In vivo studies have shown changes in microbial communities due to quercetin or rice bran 
and describe the improvement of colonization resistance and reduction of colon cancer (11, 
14, 53). However, these studies are marked by high variations of the microbiota 
composition likely due to host factors. Additionally, very little is known about the 
combined effect of quercetin and quercetin on gut microbiota. Thus, we focused on 
understanding the impact of quercetin and rice bran separately and in combination using a 
minibioreactor array model (32). Also, to gain insights into taxonomical composition, we 
performed 16S rRNA sequencing over time and shotgun metagenome sequencing at the 
endpoint.  
 
Using modified BHI medium, we were able to capture 30.93 % of the total amplicon 





slightly higher than previous results where the MBRA cultivated only 15-25% of the initial 
fecal community (29). The reason for the higher number of cultivated bacteria may be due 
to the modified BHI medium which has been shown to cultivate a wide range of gut bacteria 
(31). On the other hand, the highly dominant Prevotellaceae was lost in all four conditions 
in this study suggesting that fermenter adapted communities can lose much of their initial 
diversity (54). The alpha diversity indicated that the richness of the communities in 
bioreactors stabilized by day 14 (Supplementary Figure 1B). However, the taxonomical 
differences were evident as early as day four following inoculation. The changes in the 
relative abundances of taxa after day 14 were lower in control and quercetin supplemented 
medium whereas rice bran and combined quercetin with rice bran conditions had a more 
homogenized microbial composition after day 4 (Figure 2A). This indicates that the time 
required for the stabilization of communities may vary with the substrate used in 
minibioreactors in contrast to the previously determined timeframe of one week following 
fecal inoculation (29). Such changes in the time required for stabilization and diversity 
between the groups can be attributed ecologically to the stochastic rearrangement of the 
microbial species and their interactions at early stages because of selection pressure by 
substrate (55). 
 
Rice bran is a nutrient-dense food with a unique profile and ratio of bioactive 
phytochemicals such as gamma oryzanol, tocotrienols, ferulic acid, vitamin B, beta-
sitosterol and many others (12). It has been reported to be effective in preventing 
Salmonella typhimurium  (9, 14, 56), rotavirus (57, 58) and norovirus (15) infections by 





effect on gut microbiota and the reports have striking differences. In a clinical trial, 
Zambrana et al., (2019) showed significant enrichment of Veillonella, Megasphaera and 
Dialister species at the genus level from gut samples of children from either Nicaragua or 
Mali at 12 months’ time (24). Another study by Sheflin et al., (2015) showed a significant 
increase in the abundance of Methanobrevibacter smithii, Paraprevotella clara, 
Ruminococcus flavefaciens, Dialister succinatiphilus, Bifidobacterium sp., Clostridium 
glycolicum, Barnesiella intestinihominis, Anaerostipes caccae and Ruminococcus bromii 
OTUs after heat stabilized rice bran was fed to people (3 g/day) (25). The differences in 
the enriched taxa could be because of the unique inoculum used in this study. However, 
both above studies had lower resolution and report enrichment of different taxa which 
could be attributed to a different variety of rice bran being used and individualized host 
factors (59-61). The compounding hosts’ factors along with variation in age and geography 
(62), diet pattern (63), lifestyle (64-66), etc. play a crucial role in determining the gut 
microbiota composition, thus masking the actual effect of the substrate alone upon the 
diverse community. In contrast, this study supplies species-level resolution eliminating 
host interference and shows Veillonella Prevotella, Dialister, Bacteroides and Alistipes 
species are significantly enriched while Oscillibacter, Eubacterium and Citrobacter 
species are significantly reduced (Supplementary Figure 3B).   
 
Similar to rice bran, previous studies analyzing microbial composition after quercetin 
supplementation yielded variable results among different hosts. Enterobacteriaceae and 
Fusobacteriaceae were reported to be positively related to quercetin supplementation 





However, Lei et al., (2019) reported an increase in abundances of Bifidobacterium, 
Bacteroides, Lactobacillus and Clostridium, with a reduction of  Fusobacterium and 
Enterococcus in mice fed with quercetin (11). With higher resolution and removal of host 
factors, our results contrast with both studies and show enrichment of Acidaminococcus 
intestini and decreased abundances of E. limosum, E. faecalis, A. caccae, D. longicatena 
and C. catus. The domination of Enterobacteriaceae in medium supplemented with 
quercetin (Figure 2A, Supplementary Figure 3C) might have resulted in lower enrichment 
of the bacterial taxa as Enterobacteriaceae has been reported to affect quercetin 
metabolism by directly or indirectly inhibiting quercetin degrading bacteria (26). 
 
When the combined effect of quercetin and rice bran were analyzed, we find that majority 
of the microbial shift is due to the supplementation of rice bran (Figure 2, 3, Supplementary 
Figure 2). Most of the taxa enriched or decreased in the combination were very similar to 
those affected by rice bran supplementation alone. Compared to quercetin and rice bran 
supplementation separately, the combination was observed to significantly reduce 
members of the Enterobacteriaceae family (Escherichia and Citrobacter sp.) 
(Supplementary Table 1, Figure 6). Enterobacteriaceae consists of class of pathogens that 
are low in abundance but have potential to grow and dominate during dysbiotic conditions 
(67-69). The reduction of Enterobacteriaceae by combined quercetin and rice bran 
suggests a possibly beneficial effect on the host.  
 
The reduction of Enterobacteriaceae members was highly correlated with greater 





Propionate, along with other SCFAs produced by the gut microbiota, has been previously 
implicated in regulating the intestinal morphology and functions (70). Interestingly, unlike 
butyrate that is used as an energy source for the colonocytes, the health benefits of 
propionate are not restricted to the colon. Propionate has been shown to decrease liver 
lipogenesis, and hepatic and plasma cholesterol levels in rats. It has also been implicated 
in reducing obesity, by stimulating satiety in mice models. Importantly, propionate has also 
been demonstrated as a potential anti-inflammatory and anti-cancer agent. The reported 
anti-inflammatory abilities of propionate are suggested to occur through the inhibition of 
Nuclear Factor-Kappa B and suppression of IL-6 mRNA and other immune-related gene 
expression, while its anti-cancer effects are thought to occur through inhibition of Histone 
Deacetylases (HDACs) and regulation of the AP-1 pathway (71-73). Therefore, our 
observations of increased propionate levels, along with previous reports on the health 
benefits of propionate, demonstrates the importance of both flavonoids and fiber in the diet. 
This study, for the first time, reports the combined effect of quercetin and rice bran on the 
gut microbial composition in the absence of interfering host factors. Here, we report that 
the gut microbial composition was altered favorably by quercetin and rice bran to result in 
a significant reduction of opportunistic pathogens that could potentially provide additional 











Overall, the combined effect of quercetin and rice bran to shift gut microbiota to reduce 
Enterobacteriaceae was correlated with higher levels of propionate production in vitro. 
Even though the impact of these dietary ingredients separately is described to be beneficial 
to human health, their combined effect was not known. Our results show that a combination 
of substrates such as quercetin and rice bran will be beneficial in excluding enteric 
pathogens in the gut. However, it is crucial to culture, isolate and characterize the bacteria 
enriched in quercetin and rice bran supplemented medium to develop potential synbiotic 
formulations for gut health and immunity. Further, in vivo validation of such a combination 
would be necessary to understand its implication on the host.  
 
Raw sequence data from 16S rRNA amplicon sequencing and shotgun metagenome 
sequencing associated with this study has been deposited in NCBI Sequence Read Archive 
















1. Maji A, Misra R, Dhakan DB, Gupta V, Mahato NK, Saxena R, Mittal P, Thukral 
N, Sharma E, Singh A, Virmani R, Gaur M, Singh H, Hasija Y, Arora G, Agrawal 
A, Chaudhry A, Khurana JP, Sharma VK, Lal R, Singh Y. 2018. Gut microbiome 
contributes to impairment of immunity in pulmonary tuberculosis patients by 
alteration of butyrate and propionate producers. Environ Microbiol 20:402-419. 
2. Pulikkan J, Maji A, Dhakan DB, Saxena R, Mohan B, Anto MM, Agarwal N, Grace 
T, Sharma VK. 2018. Gut Microbial Dysbiosis in Indian Children with Autism 
Spectrum Disorders. Microb Ecol 76:1102-1114. 
3. Gentile CL, Weir TL. 2018. The gut microbiota at the intersection of diet and 
human health. Science 362:776-780. 
4. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling 
AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh 
PJ. 2014. Diet rapidly and reproducibly alters the human gut microbiome. Nature 
505:559-63. 
5. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. 2009. The effect 
of diet on the human gut microbiome: a metagenomic analysis in humanized 
gnotobiotic mice. Sci Transl Med 1:6ra14. 
6. Dhakan DB, Maji A, Sharma AK, Saxena R, Pulikkan J, Grace T, Gomez A, Scaria 
J, Amato KR, Sharma VK. 2019. The unique composition of Indian gut 
microbiome, gene catalogue, and associated fecal metabolome deciphered using 





7. Slavin J. 2013. Fiber and prebiotics: mechanisms and health benefits. Nutrients 
5:1417-35. 
8. Gibson GR, Roberfroid MB. 1995. Dietary modulation of the human colonic 
microbiota: introducing the concept of prebiotics. J Nutr 125:1401-12. 
9. Goodyear A, Kumar A, Ehrhart EJ, Swanson KS, Grusak MA, Leach JE, Dow SW, 
McClung A, Ryan EP. 2015. Dietary rice bran supplementation prevents 
Salmonella colonization differentially across varieties and by priming intestinal 
immunity. Journal of Functional Foods 18:653-664. 
10. Henderson AJ, Kumar A, Barnett B, Dow SW, Ryan EP. 2012. Consumption of 
rice bran increases mucosal immunoglobulin A concentrations and numbers of 
intestinal Lactobacillus spp. J Med Food 15:469-75. 
11. Lin R, Piao M, Song Y. 2019. Dietary Quercetin Increases Colonic Microbial 
Diversity and Attenuates Colitis Severity in Citrobacter rodentium-Infected Mice. 
Front Microbiol 10:1092. 
12. Zarei I, Brown DG, Nealon NJ, Ryan EP. 2017. Rice Bran Metabolome Contains 
Amino Acids, Vitamins & Cofactors, and Phytochemicals with Medicinal and 
Nutritional Properties. Rice (N Y) 10:24. 
13. Islam J, Koseki T, Watanabe K, Ardiansyah, Budijanto S, Oikawa A, Alauddin M, 
Goto T, Aso H, Komai M, Shirakawa H. 2017. Dietary Supplementation of 
Fermented Rice Bran Effectively Alleviates Dextran Sodium Sulfate-Induced 





14. Kumar A, Henderson A, Forster GM, Goodyear AW, Weir TL, Leach JE, Dow 
SW, Ryan EP. 2012. Dietary rice bran promotes resistance to Salmonella enterica 
serovar Typhimurium colonization in mice. BMC Microbiol 12:71. 
15. Lei S, Ramesh A, Twitchell E, Wen K, Bui T, Weiss M, Yang X, Kocher J, Li G, 
Giri-Rachman E, Trang NV, Jiang X, Ryan EP, Yuan L. 2016. High Protective 
Efficacy of Probiotics and Rice Bran against Human Norovirus Infection and 
Diarrhea in Gnotobiotic Pigs. Front Microbiol 7:1699. 
16. D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. 
2007. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 
43:348-61. 
17. Stewart LK, Soileau JL, Ribnicky D, Wang ZQ, Raskin I, Poulev A, Majewski M, 
Cefalu WT, Gettys TW. 2008. Quercetin transiently increases energy expenditure 
but persistently decreases circulating markers of inflammation in C57BL/6J mice 
fed a high-fat diet. Metabolism 57:S39-46. 
18. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Galvez J, Zarzuelo A. 
2005. In vivo quercitrin anti-inflammatory effect involves release of quercetin, 
which inhibits inflammation through down-regulation of the NF-kappaB pathway. 
Eur J Immunol 35:584-92. 
19. Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, 
Wagner AE, Frank J, Schrezenmeir J, Rimbach G, Wolffram S, Muller MJ. 2009. 
Quercetin reduces systolic blood pressure and plasma oxidised low-density 





disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br 
J Nutr 102:1065-74. 
20. Darband SG, Kaviani M, Yousefi B, Sadighparvar S, Pakdel FG, Attari JA, 
Mohebbi I, Naderi S, Majidinia M. 2018. Quercetin: A functional dietary flavonoid 
with potential chemo-preventive properties in colorectal cancer. J Cell Physiol 
233:6544-6560. 
21. Linsalata M, Orlando A, Messa C, Refolo MG, Russo F. 2010. Quercetin inhibits 
human DLD-1 colon cancer cell growth and polyamine biosynthesis. Anticancer 
Res 30:3501-7. 
22. Hong Z, Piao M. 2018. Effect of Quercetin Monoglycosides on Oxidative Stress 
and Gut Microbiota Diversity in Mice with Dextran Sodium Sulphate-Induced 
Colitis. Biomed Res Int 2018:8343052. 
23. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, 
Lines TC. 2007. A critical review of the data related to the safety of quercetin and 
lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic 
properties. Food Chem Toxicol 45:2179-205. 
24. Zambrana LE, McKeen S, Ibrahim H, Zarei I, Borresen EC, Doumbia L, Boré A, 
Cissoko A, Douyon S, Koné K, Perez J, Perez C, Hess A, Abdo Z, Sangaré L, 
Maiga A, Becker-Dreps S, Yuan L, Koita O, Vilchez S, Ryan EP. 2019. Rice bran 
supplementation modulates growth, microbiota and metabolome in weaning 
infants: a clinical trial in Nicaragua and Mali. Scientific Reports 9:13919. 
25. Sheflin AM, Borresen EC, Wdowik MJ, Rao S, Brown RJ, Heuberger AL, 





stabilized rice bran modulates stool microbiota and metabolites in healthy adults. 
Nutrients 7:1282-300. 
26. Tamura M, Hoshi C, Kobori M, Takahashi S, Tomita J, Nishimura M, Nishihira J. 
2017. Quercetin metabolism by fecal microbiota from healthy elderly human 
subjects. PLoS One 12:e0188271. 
27. Zoetendal EG, Akkermans AD, De Vos WM. 1998. Temperature gradient gel 
electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and 
host-specific communities of active bacteria. Appl Environ Microbiol 64:3854-9. 
28. Chung WSF, Walker AW, Vermeiren J, Sheridan PO, Bosscher D, Garcia-
Campayo V, Parkhill J, Flint HJ, Duncan SH. 2019. Impact of carbohydrate 
substrate complexity on the diversity of the human colonic microbiota. FEMS 
Microbiol Ecol 95. 
29. Auchtung JM, Robinson CD, Britton RA. 2015. Cultivation of stable, reproducible 
microbial communities from different fecal donors using minibioreactor arrays 
(MBRAs). Microbiome 3:42. 
30. PNAS. 2017. Environmental Chemicals, the Human Microbiome, and Health Risk: 
A Research Strategy. In PNAS (ed), Environmental Chemicals, the Human 
Microbiome, and Health Risk: A Research Strategy doi:10.17226/24960, 
Washington (DC). 
31. Ghimire S, Roy C, Wongkuna S, Antony L, Maji A, Keena MC, Foley A, Scaria J. 
2020. Identification of Clostridioides difficile-Inhibiting Gut Commensals Using 





32. Auchtung JM, Robinson CD, Farrell K, Britton RA. 2016. MiniBioReactor Arrays 
(MBRAs) as a Tool for Studying C. difficile Physiology in the Presence of a 
Complex Community. Methods Mol Biol 1476:235-58. 
33. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, 
Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, 
Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodríguez AM, 
Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM, Durall DM, 
Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM, Gibbons 
SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H, 
Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang 
KB, Keefe CR, Keim P, Kelley ST, Knights D, et al. 2019. Reproducible, 
interactive, scalable and extensible microbiome data science using QIIME 2. 
Nature Biotechnology 37:852-857. 
34. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. 2016. 
DADA2: High-resolution sample inference from Illumina amplicon data. Nat 
Methods 13:581-3. 
35. Katoh K, Misawa K, Kuma K, Miyata T. 2002. MAFFT: a novel method for rapid 
multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 
30:3059-66. 
36. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2--approximately maximum-
likelihood trees for large alignments. PLoS One 5:e9490. 
37. Team RC. 2017. R: A language and environment for statistical computing. R 





38. McMurdie PJ, Holmes S. 2013. phyloseq: an R package for reproducible interactive 
analysis and graphics of microbiome census data. PLoS One 8:e61217. 
39. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley 
GA, Gregory Caporaso J. 2018. Optimizing taxonomic classification of marker-
gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome 
6:90. 
40. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, 
Andersen GL, Knight R, Hugenholtz P. 2012. An improved Greengenes taxonomy 
with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. 
ISME J 6:610-8. 
41. Uritskiy GV, DiRuggiero J, Taylor J. 2018. MetaWRAP—a flexible pipeline for 
genome-resolved metagenomic data analysis. Microbiome 6:158. 
42. Menzel P, Ng KL, Krogh A. 2016. Fast and sensitive taxonomic classification for 
metagenomics with Kaiju. Nat Commun 7:11257. 
43. Mende DR, Letunic I, Huerta-Cepas J, Li SS, Forslund K, Sunagawa S, Bork P. 
2017. proGenomes: a resource for consistent functional and taxonomic annotations 
of prokaryotic genomes. Nucleic Acids Res 45:D529-D534. 
44. Robertson CE, Harris JK, Wagner BD, Granger D, Browne K, Tatem B, Feazel 
LM, Park K, Pace NR, Frank DN. 2013. Explicet: graphical user interface software 
for metadata-driven management, analysis and visualization of microbiome data. 
Bioinformatics 29:3100-1. 
45. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and 





46. Gupta A, Dhakan DB, Maji A, Saxena R, P.K. VP, Mahajan S, Pulikkan J, Kurian 
J, Gomez AM, Scaria J, Amato KR, Sharma AK, Sharma VK. 2019. Association 
of Flavonifractor plautii, a Flavonoid-Degrading Bacterium, with the Gut 
Microbiome of Colorectal Cancer Patients in India. mSystems 4:e00438-19. 
47. Braune A, Blaut M. 2016. Bacterial species involved in the conversion of dietary 
flavonoids in the human gut. Gut Microbes 7:216-34. 
48. Sonnenburg JL, Backhed F. 2016. Diet-microbiota interactions as moderators of 
human metabolism. Nature 535:56-64. 
49. Sonnenburg ED, Sonnenburg JL. 2014. Starving our microbial self: the deleterious 
consequences of a diet deficient in microbiota-accessible carbohydrates. Cell 
Metab 20:779-786. 
50. Hung CC, Garner CD, Slauch JM, Dwyer ZW, Lawhon SD, Frye JG, McClelland 
M, Ahmer BM, Altier C. 2013. The intestinal fatty acid propionate inhibits 
Salmonella invasion through the post-translational control of HilD. Mol Microbiol 
87:1045-60. 
51. Sorbara MT, Dubin K, Littmann ER, Moody TU, Fontana E, Seok R, Leiner IM, 
Taur Y, Peled JU, van den Brink MRM, Litvak Y, Baumler AJ, Chaubard JL, 
Pickard AJ, Cross JR, Pamer EG. 2019. Inhibiting antibiotic-resistant 
Enterobacteriaceae by microbiota-mediated intracellular acidification. J Exp Med 
216:84-98. 
52. El Hage R, Hernandez-Sanabria E, Calatayud Arroyo M, Props R, Van de Wiele T. 





a Dynamic in vitro Model of the Human Intestinal Microbial Ecosystem. Front 
Microbiol 10:1206. 
53. Zhang XA, Zhang S, Yin Q, Zhang J. 2015. Quercetin induces human colon cancer 
cells apoptosis by inhibiting the nuclear factor-kappa B Pathway. Pharmacogn Mag 
11:404-9. 
54. McDonald JA, Schroeter K, Fuentes S, Heikamp-Dejong I, Khursigara CM, de Vos 
WM, Allen-Vercoe E. 2013. Evaluation of microbial community reproducibility, 
stability and composition in a human distal gut chemostat model. J Microbiol 
Methods 95:167-74. 
55. Vellend M. 2010. Conceptual synthesis in community ecology. Q Rev Biol 85:183-
206. 
56. Rubinelli PM, Kim SA, Park SH, Roto SM, Nealon NJ, Ryan EP, Ricke SC. 2017. 
Differential effects of rice bran cultivars to limit Salmonella Typhimurium in 
chicken cecal in vitro incubations and impact on the cecal microbiome and 
metabolome. PLoS One 12:e0185002. 
57. Yang X, Twitchell E, Li G, Wen K, Weiss M, Kocher J, Lei S, Ramesh A, Ryan 
EP, Yuan L. 2015. High protective efficacy of rice bran against human rotavirus 
diarrhea via enhancing probiotic growth, gut barrier function, and innate immunity. 
Sci Rep 5:15004. 
58. Nealon NJ, Yuan L, Yang X, Ryan EP. 2017. Rice Bran and Probiotics Alter the 
Porcine Large Intestine and Serum Metabolomes for Protection against Human 





59. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, 
Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, 
Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren 
W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI. 2013. Gut 
microbiota from twins discordant for obesity modulate metabolism in mice. 
Science 341:1241214. 
60. Stewart JA, Chadwick VS, Murray A. 2005. Investigations into the influence of 
host genetics on the predominant eubacteria in the faecal microflora of children. J 
Med Microbiol 54:1239-42. 
61. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont 
M, Van Treuren W, Knight R, Bell JT, Spector TD, Clark AG, Ley RE. 2014. 
Human genetics shape the gut microbiome. Cell 159:789-99. 
62. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras 
M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, 
Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, 
Knights D, Knight R, Gordon JI. 2012. Human gut microbiome viewed across age 
and geography. Nature 486:222-7. 
63. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, 
Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, 
Nessel L, Li H, Bushman FD, Lewis JD. 2011. Linking long-term dietary patterns 
with gut microbial enterotypes. Science 334:105-8. 
64. Cook MD, Allen JM, Pence BD, Wallig MA, Gaskins HR, White BA, Woods JA. 





cell homeostasis and microbiome characteristics with exercise training. Immunol 
Cell Biol 94:158-63. 
65. Benedict C, Vogel H, Jonas W, Woting A, Blaut M, Schurmann A, Cedernaes J. 
2016. Gut microbiota and glucometabolic alterations in response to recurrent partial 
sleep deprivation in normal-weight young individuals. Mol Metab 5:1175-1186. 
66. Karl JP, Margolis LM, Madslien EH, Murphy NE, Castellani JW, Gundersen Y, 
Hoke AV, Levangie MW, Kumar R, Chakraborty N, Gautam A, Hammamieh R, 
Martini S, Montain SJ, Pasiakos SM. 2017. Changes in intestinal microbiota 
composition and metabolism coincide with increased intestinal permeability in 
young adults under prolonged physiological stress. Am J Physiol Gastrointest Liver 
Physiol 312:G559-G571. 
67. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, 
Dore J. 2003. Alterations of the dominant faecal bacterial groups in patients with 
Crohn's disease of the colon. Gut 52:237-42. 
68. Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, 
Brostoff J, Parkhill J, Dougan G, Petrovska L. 2011. High-throughput clone library 
analysis of the mucosa-associated microbiota reveals dysbiosis and differences 
between inflamed and non-inflamed regions of the intestine in inflammatory bowel 
disease. BMC Microbiol 11:7. 
69. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin 
KA, Socci ND, Viale A, Perales MA, Jenq RR, van den Brink MR, Pamer EG. 
2012. Intestinal domination and the risk of bacteremia in patients undergoing 





70. Scheppach W. 1994. Effects of short chain fatty acids on gut morphology and 
function. Gut 35:S35-8. 
71. Hosseini E, Grootaert C, Verstraete W, Van de Wiele T. 2011. Propionate as a 
health-promoting microbial metabolite in the human gut. Nutr Rev 69:245-58. 
72. Tedelind S, Westberg F, Kjerrulf M, Vidal A. 2007. Anti-inflammatory properties 
of the short-chain fatty acids acetate and propionate: a study with relevance to 
inflammatory bowel disease. World J Gastroenterol 13:2826-32. 
73. Nepelska M, Cultrone A, Beguet-Crespel F, Le Roux K, Dore J, Arulampalam V, 
Blottiere HM. 2012. Butyrate produced by commensal bacteria potentiates phorbol 





















CHAPTER 4: CLOSTRIDIUM SCINDENS INHIBITS CLOSTRIDIOIDES 
DIFFICILE BY BILE ACID DEPENDENT AND INDEPENDENT 
MECHANISMS: GENETIC AND PHENOTYPIC ANALYSIS 
Sudeep Ghimire 1,2, Kinchel C. Doerner 3, Jennifer M. Auchtung 4, Robert A. Britton 5, 
Joy Scaria 1,2* 
 
 
1Department of Veterinary and Biomedical Sciences, South Dakota State University, 
Brookings, SD, USA. 
2South Dakota Center for Biologics Research and Commercialization, SD, USA. 
3Department of Biology and Microbiology, South Dakota State University, Brookings, 
SD, USA. 
4Department of Food Science and Technology, University of Nebraska, Lincoln, NE, 
USA. 
5Department of Molecular Virology and Microbiology, Baylor College of Medicine, 
Houston, TX, USA 
 
 






Clostridioides (Clostridium) difficile is a gram-positive, endospore-forming, anaerobic rod 
that causes severe gastrointestinal disease resulting in thousands of deaths every year 
worldwide. It is the most common cause of hospital acquired diarrhea with a 15-30% 
relapsing rate.  C. difficile growth is inhibited by the secondary bile acids deoxycholic acid 
and lithocholic acid. Clostridium scindens, an intestinal bacterium capable of 7-α-
dehyroxylation of primary bile acids (i.e., cholic and chenodeoxycholic acids) to secondary 
bile acids, has demonstrated promise to treat C. difficile infections.  This study compares 
genetic diversity among five C. scindens strains and uses batch and continuous flow mini-
bioreactor culture systems to determine the ability of these strains to inhibit the growth of 
C. difficile strain R20291.  All five strains inhibited C. difficile R20291, with two distinct 
mechanisms observed. Two C. scindens strains directly inhibited C. difficile R20291 in the 
absence of cholic acid but also inhibited C. difficile R20291 in a dose dependent manner 
when cholic acid was included.  Three C. scindens strains directly inhibited C. difficile 
R20291 but did not further inhibit when cholic acid was added. Filter-sterilized culture 
supernatant from each of the five C. scindens strains inhibited growth of C. difficile R20291 
when added to the growth media of C. difficile R20291, but inhibition was significantly 
reduced when heat treated culture supernatant was used indicating the presence of heat-
labile inhibitors in the culture supernatant.  Results indicate that C. scindens inhibits C. 








Clostridium scindens is normally found in the gastrointestinal tracts of humans and 
modifies bile acids produced by the host.  These modified bile acids are thought to inhibit 
the growth of Clotridioides (Clostridium difficile), a potent intestinal pathogen.  Here, we 
study the genomes of five strains of C. scindens, perform a genome wide analysis for each 
strain, and determine if C. scindens inhibits C. difficile.  Results indicate that all C. scindens 
strains tested inhibit C. difficile growth by production of secretory extracellular alkaloids. 
The presence of bile acids enhances C. difficile inhibition by two C. scindens strains.  
Substantial differences in the nature and the degree of inhibition of C. scindens against C. 
difficile are observed. Such metabolic and genetic variations in capabilities of C. scindens 
strains to inhibit C. difficile is an important consideration during C. difficile infection 
treatments. Utilizing C. scindens strains to inhibit C. difficile through bile acid-independent 














Clostridioides (Clostridium) difficile is a Gram-positive, endospore forming bacterium 
producing mild to severe diarrhea leading to pseudomembranous colitis and death (1).  In 
the United States, C. difficile causes 450,000 infections and 29,000 deaths annually (2).  C. 
difficile infection can be effectively treated by vancomycin and fidaxomicin (3), however, 
use of these and other antibiotics perturb the intestinal microbial community which may 
increase the severity of the C. difficile infection (4).  Furthermore, following antibiotic 
treatment, 15-30% of C. difficile infections relapse into an active infection (3, 5). Fecal-
microbiota transplantation has been recommended as an alternative therapy against such 
relapsing infections with ~90% success rate (6-8). Use of fecal microbiota transplantation 
is debated among scientists because of the variable bacterial community of the fecal 
transplant, difference in the recipient genotype (9), potential for transfer of pathogens (10),  
differences in dosage and administration methods.  A better understanding of the colonic 
microbiota and how fecal microbiota transplantation therapy is effective would be 
advantageous.  Recently, the microbial metabolism of bile acids has been recognized as 
being an important component of C. difficile control in the intestine. 
 
Bile acids are synthesized in the liver from cholesterol and secreted into the proximal small 
intestine as a component of bile.  The primary bile acids in humans are cholic acid (CA; 
3α,7α,12α-trihydroxy-5β-cholanic acid) and chenodeoxycholic acid (CDCA; 3α,7α-
dihydroxy-5β-cholanic acid) each of which are conjugated to glycine or taurine in the liver 
at the 3 position.  While in the small intestine, bile acids aid in the absorption of lipids and 





returned to the liver via enterohepatic circulation.  Approximately 5% of bile acids escape 
reabsorption and enter the colon and are exposed to the colonic microflora (11). Many 
colonic bacterial species are known to deconjugate both the glycine and taurine moieties 
resulting in free CA and CDCA (12).  These free bile acids, in turn, undergo a variety of 
oxidation-reduction reactions but the most quantitatively important and irreversible 
reaction is 7α-dehydroxylation of primary bile acids to secondary bile acids (11).  This 
reaction generates (DCA; 3α,12α-dihydroxy-5β-cholanic acid) from CA and lithocholic 
acid (LCA; 3α-hydroxy-5β-cholanic acid) from CDCA.   
 
Both primary and secondary bile acids are reported to affect C. difficile germination and 
outgrowth.  Microscopic examination indicates taurocholic acid (TCA), CA, and DCA 
facilitate germination of C. difficile endospores.  CA (12 mM) and DCA (1.9 mM) each 
inhibit growth of C. difficile vegetative cells, but CA at 1.2 mM does not affect cell growth 
on agar plates (13, 14).   These observations have led to improved endospore recovery and 
germination on selective agar plates for clinical testing (13). 
 
Secondary bile acids have been reported to inhibit C. difficile. Studer et al. (15) 
demonstrated that a combination of 12 murine intestinal isolates, when given to germ free 
mice, are not protective against a C. difficile challenge but addition of C. scindens, an 
intestinal species known to 7α-dehydroxylate bile acids (16), to the microbial mix was 
protective during the early stages of infection.  Using a comprehensive analysis of murine 





of C. difficile growth.  Additionally, these workers used an in vivo murine model to show 
C. scindens was protective against a C. difficile infection and DCA was also correlated 
with C. scindens and inhibition of C. difficile.   In contrast to the bile acid theory, Kang et 
al. (18) observed that C. difficile inhibited C. scindens growth in culture by secretion of 
proline-base cyclic peptide antimicrobials  and, surprisingly, that at least two strains of bile 
acid 7α-dehydroxylating bacteria, C. scindens ATCC 35704 and C. sordellii ATCC 9714, 
secrete tryptophan-derived antimicrobial peptides which inhibit C. difficile. Although, C. 
scindens associated production of DCA in the colon has been shown to provide protection 
against C. difficile (15, 17), high accumulation of DCA is toxic to colonocytes (19). 
Colonocytes undergo major changes in their DNA and metabolism properties that affects 
cell division to produce colon cancer (20-25). High levels of DCA can predispose to colon 
cancer, the third most common cause of cancer death in the US (26, 27).  
 
This study compares the genomes of 5 strains of C. scindens and tests their ability to inhibit 
C. difficile R20291, a hypervirulent ribotype 027 strain, in both batch and continuous 
culture.  C. scindens ATCC 35704 was originally isolated from feces from a health human 
subject and shown to convert 17-hydroxylated corticoids to androstans (C19 corticoids) 
and also exhibits bile acid 7α-dehydroxylation (15).  C. scindens TH82, C. scindens M18, 
C. scindens I10, and C. scindens Y1113 were also isolated from feces from a healthy human 
and possess bile acid 7α-dehydroxylation activity (28, 29).  All strains exhibit high levels 
of bile acid 7α-dehydroxylation activity (30) but otherwise exhibit unique phenotypic or 
metabolic characteristics (28, 29). Our results show that among these C. scindens strains, 





Materials and Methods 
Strains and culture conditions: C. scindens TH82, C. scindens M18, C. scindens Y1113, 
C. scindens I10 were originally obtained from the P.B. Hylemon (Virgina Commonwealth 
University, Richmond, VA USA).  C. scindens ATCC 35704 was purchased from 
American Type Culture Collection (Manassas, VA, USA).  C. difficile R20291 was 
obtained from the laboratory Dr. Trevor Lawley (Sanger Institute, UK).  Brain Heart 
Infusion broth modified (BHIM) was prepared as indicated:  37 g/L brain heart extract, 
5.0g/L yeast extract, 10.0g/L pectin, 10.0g/L inulin , 0.3 g/L L-cysteine, 0.25 mg/L 
resazurin, and 1.0 mg/L menadione was added to 900 ml water, pre-reduced and sterilized 
by autoclaving at 121oC and 15 psi for 30 min. Following autoclaving, 100 ml of filter 
sterilized 4-morpholinoethanesulfonic acid hydrate (1 M, MES hydrate) was added as the 
buffering agent and pH was adjusted to 6.8 using 10 M sodium hydroxide. Finally, 1.7ml 
of acetate (30 mM), 2ml of propionate (8 mM), 2ml butyrate (4mM), 100µl isovalerate 
(1mM), 1ml hemin (0.5 mg/ml), 10 ml of ATCC vitamin and ATCC mineral mixtures 
respectively were added per liter of media.  All cultures were manipulated using an 
anaerobic chamber (Coy Lab Products, Grass Lake, MI) containing 5% CO2, 10% H2, and 
85% N2 maintained at 37
oC.  
 
Genome sequencing assembly, annotation, comparative analysis and secondary 
metabolite prediction:   To generate high quality genomes, strains were sequenced using 
Illumina short read  (Illumina Inc, CA) and the Oxford Nanopore MinION long read (SQL-
LSK108, Oxford Nanopore technologies, UK) sequencing technologies. For Illumina 





Bacterial DNA Kit (Omega Biotek, GA). Sequencing library was then prepared using 
Nextera XT Kit (Illumina Inc, CA).  Libraries were sequenced using 250 base paired end 
chemistry on an Illumina MiSeq platform.  FASTQ files were generated using Casava 
v1.8.2 pipeline (Illumina, Inc, CA).  
 
High molecular weight DNA required for MinION sequencing was extracted following 
modified phenol: chloroform method as described previously (41). High molecular weight 
DNA was quantified using Qubit dsDNA HS assay kit (Invitrogen, OR) kit and Qubit® 
3.0 Flurometer (Thermo Fisher Scientific Inc., MA). For Oxford Nanopore sequencing, 
1.5-2.0 µg of high molecular weight DNA was fragmented by centrifugation using G-tube 
(Covaris Inc., MA), and the ends were repaired using NEBNext End Repair/dA-Tailing 
Module followed by ligation of adapters.  MinION long read sequencing was performed 
using the 1-directional (1D) sequencing kit according to manufacturer’s protocol (SQL-
LSK108, Oxford Nanopore technologies, UK).  
 
To compare the genetic makeup of the C. scindens strains, hybrid genomes were generated 
using short and long reads. Initially, long reads were assembled using miniasm (42). The 
assembled long reads were then used to scaffold assembly of the short reads using 
Unicycler v 0.4.0 (43) to produce hybrid assembly. Genomic features were evaluated and 
validated from hybrid sequences using Quast (44). Total number of tRNAs were predicted 
using ARAGORN (45). Also, the assembled genome sequences were annotated using 





obtained from RAST were used to calculate identities between the sequences using two 
way Amino Acid Identity (AAI) calculator with minimum identity of 20% (47).  To 
determine the diversity and variations of bile acid inducible (bai) genes which are 
responsible for bile acid 7α-dehydroxylation, the hybrid genomes of five C. scindens 
strains were separately examined for the presence of bai genes using CLC genomics 
workbench 9.5.3 (Qiagen Bioinformatics, CA) at 80% identity level. C. scindens VPI 
12708 bai operon sequences were used as reference sequences for bai genes comparison 
[GenBank: U57489.2].  Additionally, these 5 hybrid assemblies of the C. scindens strains 
were annotated using Prokka 1.13 (48). The obtained protein sequences were visualized 
using Snapgene Viewer 4.2.6 (GSL Biotech LLC) to locate bai operon. Genes baiA1, baiF, 
baiE and baiB were annotated by Prokka and remaining genes were manually located using 
blastp in nrNCBI with default parameters. Amino acid sequences of baiA1/3, baiA2, baiB, 
baiCD, baiE, baiF, baiG, baiH, baiI and baiJKL were separately aligned employing the 
ClustalO 1.2.4 web server. To identify the presence of mcbB gene encoding the production 
of 1-acetyl--carboline in C. scindens, know sequence of mcbB gene from other species 
was used for sequence search against C. scindens genomes. mcbB gene from C. innocuum 
2959 in NCBI database (accession number NZ_KB850948.1) and ten other Streptococcus 
species (McbB gene accessions: EFM29959.1, VEI59856.1, VTQ24966.1, CIZ00836.1, 
EMP71847.1, RGR60169.1, RKV90253.1, RFU54189.1, AXQ78541.1 and RFU54189.1) 
in UniprotKB database were used for homology search using CLC genomics workbench 






Batch co-culture of C. scindens strains with C. difficile:  To analyze the effect of genetic 
differences in phenotypic expression related to resistance against C. difficile, in vitro batch 
co-culture was performed.  C. scindens strains and C. difficile R20291 were maintained 
inside anaerobic chamber in BHIM medium. To examine the effect of bile acids on C. 
difficile inhibition by C. scindens, strains were co-cultured in various concentrations of CA 
and DCA.  Concentrations were similar to health human bile acid fecal water 
concentrations (49).  Cultures were grown overnight in BHIM and OD600 was adjusted to 
0.5 using BHIM.  Each C. scindens strain was inoculated with C. difficile in the ratio 9:1 
(vol/vol) in 1 ml of BHIM in triplicate. The mixture was incubated at 370C for 24 hours 
anaerobically then serially diluted and spread on C. difficile selective agar to enumerate the 
C. difficile as described before (SQL-LSK108, Oxford Nanopore technologies, UK).  
 
Co-culture of C. scindens strains with C. difficile in continuous flow mini-bioreactors: 
C. scindens strains were co-cultured in BHIM with C. difficile in continuous flow model 
using minibioreactors arrays (MBRAs) as described previously with 8 hour retention time 
(50). Similar to batch co-culture assays, C. scindens and C. difficile were mixed at a 9:1 
(vol/vol) ratio in duplicate. Co-culture of C. scindens and C. difficile were incubated CA 
(50 µg/ml; 116 μM) and BHIM with DCA (50 µg/ml; 121 μM). Samples were collected 
prior inoculation and 1, 2- and 3-days post inoculation.  Samples were enumerated for C. 
difficile. For short chain fatty acid analysis, eight hundred microliters of the bacterial 
sample from MBRAs were added to 160 µl of freshly prepared 25% (w/v) m-phosphoric 





for 30 min and 600 µl supernatant was subjected to gas chromatography (Agilent 
Technologies, USA). 
 
Testing for the production of antimicrobials from C. scindens against C. difficile 
R20291: C. scindens strains were grown for 48 hours in BHIM medium then centrifuged 
at 10,000 g for 5 min.  The supernatant was filtered using a 0.22 µm filter and moved into 
the anaerobic chamber and diluted in ratio 1:1 with the 1X BHIM medium.  pH was 
adjusted to 6.8.  An overnight culture of C. difficile R20291 was adjusted to OD600 = 0.5.  
Twenty microliters of OD600 adjusted suspension was added to 1 ml of the 1:1 diluted cell 
free supernatant (heat treated and untreated) and incubated for 24 hours in triplicate.  C. 
difficile R20291 was grown in 50% BHIM diluted with anaerobic PBS as a positive control. 
After 24 hours, the cultures were serial diluted with anaerobic PBS and plated on 
Clostridium difficile selective agar and incubated anaerobically for 24 hours for 
enumeration. To access the activity of 1- acetyl--carboline against C. difficile R20291, 
we grew the C. difficile in BHIM supplemented with 25 μg/mL of commercially available 
1-acetyl--carboline (Aobious Inc, MA) under both heat-treated (650C for 20 minutes) and 
untreated conditions in triplicate. OD630 was measured at 0, 24 and 48 hours and analyzed 
to obtain inhibition of C. difficile which was expressed as percentage inhibition compared 
to the control.  
 
Statistical analysis:  Oneway ANOVA was performed in Graphpad Prism v6.0.1. 






Genomic analysis of C. scindens strains: To gain insights into the genomic diversity that 
might impact the C. difficile inhibition capacity of C. scindens, genomes of five strains 
known to exhibit bile acid 7α-dehydroxylation activity, were sequenced. Each genome was 
sequenced using Oxford Nanopore long read and Illumina short read platforms. Hybrid 
genome assembly produced complete genomes for C. scindens I10, C. scindens M18, while 
near complete genomes were produced for C. scindens ATCC 35704, C. scindens TH82 
and C. scindens Y1113.  (Table 1). The bai genes, responsible for bile acid 7α-
dehydroxylation, were distributed in two different chromosomal regions of the C. scindens 
genomes, the first being a larger complete bai operon consisting of baiB, baiCD, baiE, 
baiA2, baiF, baiG, baiH and baiI, while second operon consisted of baiA1/3, baiJ, baiK 
and baiL. Both larger and smaller operons were present in C. scindens M18 and C. scindens 
Y1113 while only baiA1/3 was present for C. scindens ATCC 35704, C. scindens I10 and 
C. scindens TH82 (Figure 1A). The baiJKL operon was not present in C. scindens ATCC 
35704, C. scindens I10 or C. scindens TH82. In addition, a second copy of baiA2 was 
present in C. scindens ATCC 35704, C. scindens TH82 and C. scindens Y1113 but absent 
in C. scindens M18 and C. scindens I10. The baiA1/3 and baiJKL operons were separated 
in C. scindens M18 and C. scindens Y1113 by two genes, crtK-2-TspO (tryptophan rich 
sensory protein) and hcaR (LysR family transcriptional regulator) (Figure 1B). Unlike C. 
scindens VPI 12708, C. scindens M18 and C. scindens Y1113 do not possess a LysR type 
transcription regulator between the baiJKL operon and the baiA1 gene.  Furthermore, as 
upstream and downstream genes could potentially regulate gene expression, we checked 







Figure 1.  Genomic differences among the Clostridium scindens (CS) strains. A) Average 
amino acid identity of CS strains. Average amino acid identity (AAI) matrix was obtained 
using amino acid identity calculator and visualized using MeV 4.9.0. B) Presence of bile 
acid inducible (bai) genes in bai operon in different Clostridium scindens (CS) strains. 
Clostridium scindens VPI 12708 bai genes were used for comparison and % identity of 
each gene was represented as a heat map. C) Two groups of Clostridium scindens were 
formed based on the presence of baiJKL genes. The presence of baiJKL and hcaR genes 
in Clostridium scindens -M18 and Clostridium scindens Y1113 are shown compared to 
Clostridium scindens ATCC 35704, CS-I10 and CS-TH82. Two separate rows of genes 








no differences in the large operon were observed up to 8 upstream and downstream genes.  
For the second operon, genes in upstream of the baiA1 differed from -5 position whereas 
an additional hypothetical protein (winged helix DNA binding domain protein) was 
detected in downstream 6th position for only C. scindens M18 and C. scindens Y1113.  
 
Doerner et al. (30) has demonstrated the differences in the dehydroxylation of CA to DCA. 
Among these five strains, C. scindens Y1113 was observed to be the highest 
dehydroxylating bacteria followed by C. scindens I10, C. scindens M18, C. scindens ATCC 
34704 and C. scindens TH82. Such differences could be attributed to the presence of the 
bai genes in the bai operons. Even though all strains exhibited the presence of larger operon 
baiBCDEA2FGHI in this study, the difference was observed for baiJKL which might 
contribute to the differences in bile acid conversion. On other hand, the baiA1/3 was also 
present in all the strains but variation in the amino acid composition was observed. The 
baiA1/3 gene of C. scindens ATCC 35704, C. scindens I10 and C. scindens TH82 was 
determined to have 9 amino acid differences compared to C. scindens M18 and C. scindens 
Y1113 (Supp. Figure 1). The differences were in positions 25, 99, 111,118, 133, 204, 209, 
210 and 235.  Position 111 represented a change in histidine (H), present in C. scindens 
ATCC 35704, C. scindens I10 and C. scindens TH82, to asparagine (N) in C. scindens M18 
and C. scindens Y1113. At position 111, the positively charged side chain of histidine, 
present in C. scindens ATCC 35704, C. scindens I10 and C. scindens TH82, was altered to 
a polar uncharged side chain of asparagine in C. scindens M18 and C. scindens Y1113. 





CS-ATCC       MKLVQDKITIITGGTRGIGFAAAKIFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
 60 
CS-I10        MKLVQDKITIITGGTRGIGFAAAKIFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
 60 
CS-TH82       MKLVQDKITIITGGTRGIGFAAAKIFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
 60 
CS-M18        MKLVQDKITIITGGTRGIGFAAAKLFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
 60 
CS-Y1113      MKLVQDKITIITGGTRGIGFAAAKLFIENGAKVSIFGETQEEVDTALAQLKELYPEEEVL
 60 
              ************************:*********************************** 
 
CS-CSATCC     GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNTVFSRVSEEDFKHIMDINVIGV
 120 
CS-I10        GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNTVFSRVSEEDFKHIMDINVIGV
 120 
CS-TH82       GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNTVFSRVSEEDFKHIMDINVIGV
 120 
CS-M18        GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNSVFSRVSEEDFKNIMDINVNGV
 120 
CS-Y1113      GFAPDLTSRDAVMAAVGTVAQKYGRLDVMINNAGITMNSVFSRVSEEDFKNIMDINVNGV
 120 
              **************************************:***********:****** ** 
 
CS-ATCC       FNGAWSAYQCMKEAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
 180 
CS-I10        FNGAWSAYQCMKEAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
 180 
CS-TH82       FNGAWSAYQCMKEAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
 180 
CS-M18        FNGAWSAYQCMKDAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
 180 
CS-Y1113      FNGAWSAYQCMKDAKQGVIINTASVTGIYGSLSGIGYPTSKAGVIGLTHGLGREIIRKNI
 180 
              ************:*********************************************** 
 
CS-ATCC       RVVGVAPGVVDTDMTKGLPPEILDDYLKSFPMKRMLKPEEIANVYLFLASDLANGITATT
 240 
CS-I10        RVVGVAPGVVDTDMTKGLPPEILDDYLKSFPMKRMLKPEEIANVYLFLASDLANGITATT
 240 
CS-TH82       RVVGVAPGVVDTDMTKGLPPEILDDYLKSFPMKRMLKPEEIANVYLFLASDLANGITATT
 240 
CS-M18        RVVGVAPGVVDTDMTKGLPPEILEDYLKTLPMKRMLKPEEIANVYLFLASDLASGITATT
 240 
CS-Y1113      RVVGVAPGVVDTDMTKGLPPEILEDYLKTLPMKRMLKPEEIANVYLFLASDLASGITATT
 240 
              ***********************:****::***********************.****** 
 
CS-ATCC       ISVDGAYRP* 249 
CS-I10        ISVDGAYRP* 249 
CS-TH82       ISVDGAYRP* 249 
CS-M18        ISVDGAYRP* 249 
CS-Y1113      ISVDGAYRP* 249 
 
Supplementary Figure 1: Sequence alignment of amino acids of baiA1 gene for five C. 






Table 1. Genomic features of Clostridium scindens strains compared in this study. 
Features 
ATCC 
35704 I10 M18 TH82 Y1113 
Total contigs 3 1 1 141 10 
Largest contig (bp) 3,536,561 3,435,579 4,020,163 298,262 1,165,028 
Total length (bp) 3,635,563 3,435,579 4,020,163 3,321,200 3,937,901 
GC (%) 46.23 46.36 47.38 46.66 47.42 
N50 3,536,561 3,435,579 4,020,163 61,248 897,417 
L50 1 1 1 16 2 
Orthologous protein clusters 3179 3165 3690 3077 3667 
Coding sequence 3822 3548 3819 3372 3721 
RNAs 65 64 64 52 60 
















and C. scindens TH82, was substantially different than the hydrophobic side chain of 
asparagine present in C. scindens M18 and C. scindens Y1113 (Supp. Figure 1).  
 
Kang et al. (18) recently reported that C. scindens ATCC 35704 produce 1-acetyl--
carboline, which has an inhibitory effect against C. difficile.  However, this study did not 
identify the gene responsible for the production of 1-acetyl--carboline in C. scindens. In 
other organisms, mcbB  mediates the Pictet Spengler reaction of L-tryptophan and 
oxaloacetaldehyde to produce carbolines (31). To determine whether the mcbB homolog is 
present in C. scindens, we searched the genomes of all strains sequenced in this study using 
all known mcbB sequences from C. innocuum and Streptococcus species.  This search did 
not find any mcbB homolog in C. scindens when 30% sequence identity and 50% coverage 
was used as search cut off. 
 
Phenotypic analysis of C. scindens strains: All five C. scindens strains were tested for 
inhibition of growth of C. difficile R20291 using batch co-cultures with varying 
concentrations of bile acids (Figure 2). When grown in the absence of bile acid, all C. 
scindens strains significantly reduced growth of C. difficile R20291. Reduction of growth 
ranged from 8.3±0.02 log10 CFU of C. difficile R20291 grown in monoculture (control) to 
7.8±0.08 log10 when grown with C. scindens TH82 or 5.8±0.06 log10 when grown with C. 
scindens M18. Additionally, when co-cultured with C. scindens TH82 or C. scindens 
Y1113, CFUs of C. difficile R20291 were reduced in a dose-dependent manner when 






Figure 2. Growth of Clostridioides (Clostridium) difficile (CD) when tested using batch 
co-culture with Clostridium scindens (CS) strains in the presence and absence of cholic 
acid (CA) and deoxycholic acid (DCA).  Clostridium difficile monoculture and all CS 
cocultures in the presence of DCA are shown in red; ‘a’ indicates statistical significance 
(p<0.05) when compared to the corresponding control culture without DCA.  C. difficile in 
monoculture, with and without CA, is indicated by ‘b’; no significant difference of C. 






Figure 3. Levels of C. difficile R20291 when cocultured in continuous flow minibioreactor 
with C. scindens (CS) strains in the presence of cholic acid (CA) and deoxycholic acid 
(DCA). C. difficile was determined by counting colony forming units (CFU) every 24 h for 
3 days. A) BHIM medium. B) BHIM containing 50 µg/ml of CA. C) BHIM medium 
containing 50 µg/ml of DCA. Statistical analysis was performed by comparing C. difficile 
CFUs in pure culture to C. difficile CFUs in coculture.  Error bars represent standard error 
of mean of two experiment performed in duplicate. One way ANOVA and tukey test was 
performed at the 3rd day between the groups where ‘*’, ‘**’, ‘***’, and ‘****’ represent 









not increase the growth inhibition of C. difficile R20291 by C. scindens M18, C. scindens 
ATCC 35704 or C. scindens I10. Addition of DCA (50 μg/ml) reduced the growth of C. 
difficile R20291 from 8.2±0.02 log10 to 5.98 ±0.06 log10. None of the C. scindens tested 
further reduced growth of C. difficile R20291 cultured in the presence of DCA when 
compared to C. difficile R20291 grown in monoculture in the presence of DCA (Figure 2). 
 
C. scindens M18, C. scindens ATCC 35704, C. scindens Y1113, C. scindens TH82 and C. 
scindens I10 were also tested for inhibition of C. difficile R20291 grown in continuous 
flow culture using a mini-bioreactor array.  Similar to batch co-culture, all 5 C. scindens 
strain inhibited C. difficile R20291 (Figure 3A) with statistical significance (p<0.05).  C. 
scindens ATCC 35704 and C. scindens I10 were the most inhibitory, each decreasing C. 
difficile R20291 growth by 2.3 log10. Addition of CA (50 μg/ml) substantially increased C. 
difficile R20291 inhibition by C. scindens TH82 and C. scindens Y1113 but did not affect 
the inhibition of the other three C. scindens strains (Figure 3B).  DCA (50 μg/ml) 
effectively inhibited growth of C. difficile R20291 in continuous culture reducing control 
levels of 8.5±0.01 log10 CFU to 6.0 ±0.04 log10 CFU.  Furthermore, addition of C. scindens 
strains to C. difficile R20291 cultured in DCA did not significantly reduce C. difficile 
R20291 levels with the exception of C. scindens M18 which reduced growth from 6.0 
±0.04 log10 to 5.8±0.04 log10 (Figure 3C). 
 
Steady-state production of the short chain fatty acids, acetate, propionate, and butyrate was 






Figure 4. Concentrations of short chain fatty acids (SCFAs) obtained from coculture of C. 
scindens (CS) strains with C. difficile R20291 in continuous flow minibioreactor in BHIM 
medium with cholic acid (CA, 50 µg/ml) and deoxycholic acid (DCA, 50 µg/ml) in 
duplicate in two experiments. A, B and C represent concentrations of acetate, propionate 
and butyrate on day 3, respectively. Statistical comparison using Oneway ANOVA. ‘*’ 












(Figure 4).  Significant differences were not observed when CA or DCA was added to the 
culture medium for most strains.  Acetate values ranged from 28 to 45 mM.  Values ranged 
from 0.7 to 5.4 mM for propionate and 1.2 to 9.5 mM for butyrate.  However, the C. 
scindens M18 and C. difficile R20291 coculture provided two notable expectations. First, 
this coculture displayed a significant increase in acetate from 33.2 to 44.4 mM upon the 
addition of CA and, second, displayed a reduction of butyrate from 4.8 mM (control) to 1.2 
and 1.7 mM with addition CA and DCA, respectively.  Also, cocultures of C. scindens 
TH82 and C. difficile R20291 indicated a decrease of butyrate production of 7.4 mM 
(control) to 2.4 mM with addition of CA but addition of DCA did not significantly inhibit.  
 
Each C. scindens strain was tested for extracellular material which could inhibit growth of 
C. difficile R20291 (Figure 5A).  Culture supernatant was collected from each strain and 
diluted 1X with fresh medium then used as growth medium for C. difficile R20291. Data 
indicate that each strain was inhibitory; C. scindens ATCC 35704 was the most inhibitory 
and reduced C. difficile R20291 growth from 7.7±0.2 log10 to 6.9±0.04 log10 while C. 
scindens TH82 was the least inhibitory and reduced growth to 7.2±0.01 log10. As shown in 
Figure 5A, the inhibition was significantly reduced, but not abolished when culture 
supernatant was heat treated.  To determine whether heat treatment affects the inhibitory 
capacity of 1-acetyl--carboline on C. difficile, heat treated and untreated commercially 
available 1-acetyl--carboline was tested against C. difficile R20291 in identical 
conditions.  Data in Figure 5B Shows that heat treatment did not affect the inhibitory 






Figure 5.  (A) Inhibition of C. difficile R20291 (CD) by the cell free culture supernatant 
obtained from C. scindens (CS) strains cultured in BHIM medium. (B) Effect of heating 
on the C. difficile R20291 inhibition capacity of 1- acetyl--carboline. One-way ANOVA 
was used for statistical analysis and each mean value was compared to CD. “***” and 











1-acetyl--carboline are responsible for the bile acid independent inhibition of C. difficile 
R20291 by the C. scindens strains used in this study. 
 
Discussion 
Data presented here indicate that all five strains of C. scindens inhibit the growth of C. 
difficile R20291 in batch and continuous-flow culture using two different mechanisms of 
inhibition.  First, C. scindens M18, C. scindens ATCC 35704, and C. scindens I10 all 
inhibit C. difficile R20291 in the absence of CA; the presence of CA does not increase 
inhibition.   C. scindens M18 was most effective at inhibiting C. difficile growth in batch 
culture, causing up to 2.4 log10 reduction (270-fold) of C. difficile R20291 growth.  In 
continuous-flow culture, C. scindens I10 and C. scindens ATCC 35704 were more 
effective, inhibiting C. difficile R20291growth approximately 2.3 log10. Thus, the first 
mechanism of inhibition by C. scindens is bile acid independent. Second, C. scindens TH82 
and C. scindens Y1113 inhibited C. difficile R20291 in the absence of CA but showed a 
dose-dependent increase of inhibition with addition of CA in batch culture and a CA-
dependent increase in inhibition in continuous-flow culture.  In total, these results indicate 
that C. scindens TH82 and C. scindens Y1113 inhibit C. difficile R20291 by both a bile 
acid independent and bile acid dependent mechanisms and C. scindens ATCC 35704, C. 
scindens I10, and C. scindens M18 inhibit C. difficile R20291 only by a bile acid 
independent mechanism. The bile acid independent mechanism of C. scindens TH82 and 
C. scindens Y1113 is less effective at inhibiting C. difficile R20291 than the bile acid 






These two strains, in the absence of CA, were less effective than C. scindens M18, C. 
scindens ATCC 35704, or C. scindens I10 but achieved similar inhibitory effects with the 
addition of CA or DCA at 50 ug/ml.  The inhibitory action is dependent upon the bile acid 
CA and likely not due to CA directly, but due to the conversion of CA to DCA which is a 
more hydrophobic than CA and acts as detergent to disrupt cellular membranes and inhibit 
cell growth.  
 
Kang et al. (18) have proposed a model for both bile acid dependent and bile acid 
independent inhibition of C. difficile.   These workers isolated three compounds from C. 
scindens; turbomycin A and 1,1,1-tris(3-indolyl)-methane from C. scindens ATCC 9714 
and 1-acetyl-β-carboline from C. scindens ATCC 35704.  Further experiments indicated 
that turbomycin A and 1-acetyl-β-carboline effectively inhibited C. difficile ATCC R9689 
and the addition of DCA or LCA, but not CA, significantly increased this inhibition.   The 
authors propose the combination of bacteriostatic compounds produced by bile acid 7α-
dehydroxylating bacteria coupled with the detergent-like properties of hydrophobic 
secondary bile acids effectively inhibit C. difficile in vivo.      
 
Data presented here are generally consistent with this model, but inconsistencies remain.  
Kang et al. (18) show that C. scindens ATCC 35704 does not inhibit C. difficile ATCC 
R9689, in spite of the fact C. scindens ATCC 35704 is producing 1-acetyl-β-carboline.  





of C. scindens VPI 12708 to the co-culture of C. scindens ATCC 35704 and C. difficile 
ATCC R9689 did inhibit the growth of C. difficile ATCC R9689. However, it is unclear 
what factors C. scindens VPI 12708 contributed, as control co-culture experiments with C. 
scindens VPI 12708 and C. difficile ATCC R9689 were not reported.  C. scindens VPI 
12708 may have acted alone or perhaps in synergy with C. scindens ATCC 35704.  Our 
data indicate that a growing C. scindens ATCC 35704 culture or culture supernatant can 
effectively inhibit C. difficile which is consistent with this strain producing bacteriostatic 
compounds.  However, the heat treatment of culture supernatant reduced the inhibitory 
effect while heat treated 1-acetyl--carboline   did not show any reduction in inhibition. 
These data suggest that a protein mediated mechanism is present in addition to 1-acetyl-β-
carboline mediated inhibition of C. difficile R20291 by C. scindens ATCC 35704 in our 
experiments. Homology based searches using known mcbB genes responsible for the 
production of 1-acetyl-β-carboline in other bacterial species did not identify any homologs 
in all C. scindens strains used in this study. Clostridial genomes in general exhibit high 
sequence variation (32). This high sequence divergence may be the reason why homology-
based searches failed to identify 1-acetyl-β-carboline encoding gene in our searches.  
 
In a recent study, freshly isolated, clinical C. difficile strains were administered to 
conventional mice then disease severity was measured and correlated to virulence factors 
and genomic features (33).   The results indicated that pathogenic C. difficile strains 
produce a range of disease severities which are not necessarily correlated with known 
virulence factors.  For example, C. difficile intestinal burden, toxin production, sporulation 





wide variations across the strains tested. Tolerance to the secondary bile acid lithocholic 
acid was correlated with disease severity but also displayed wide variation.   The C. difficile 
RT027 genotype, which represented 6 of the 21 strains tested, was correlated with the 
greatest disease severity and mortality, except for one RT027 strain which was the least 
pathogenic of all 21 strains.  The workers went on to show that no fewer than nine groups 
of genes, other than the previously recognized pathogenicity loci, were found to correlate 
with disease severity.  Burns et al. (34) have shown that significant variation exists in the 
rate of sporulation of C. difficile strains and Heeg et al. (35) have shown that significant 
variation exists in germination of C. difficile endospores in response to bile acids and other 
factors.   These data show that virulence factors and genetic variation among C. difficile 
strains is substantial which suggests sensitivity of C. difficile strains toward bacteriostatic 
factors may vary.  While in general agreement, our data differ from other studies (18) which 
could be due to differences between the C. difficile strains employed.  This study used C. 
difficile R20291, a ‘hypervirulent’ RT027 strain isolated from a recent disease outbreak in 
the United Kingdom (36), whereas Kang et al. (18) used the ‘historic’ C. difficile R9689 
(37). In batch culture experiments, Kang et al. (18) observed C. difficile R9689 was not 
sensitive to C. scindens ATCC 35704 in the presence of CA indicating C. difficile R9689 
may not be sensitive to 1-acetyl-β-carboline at the levels produced by C. scindens ATCC 
35704.   In this study, C. scindens ATCC 35704 effectively inhibited C. difficile R20291 
(Figure 2) suggesting C. difficile R20291 is sensitive to the bacteriostatic compound, 1-
acetyl-β-carboline, at the levels produced by C. scindens ATCC 35704 (18).  Our data 
suggest C. difficile R20291 has a varied response to CA.     We show that C. difficile 





CA however when C. difficile R20291 is cultured with C. scindens ATCC 35704, C. 
scindens I10, or C. scindens M18, CA does not have an effect.  This suggests that C. 
difficile R20291 may be differentially inhibited by CA in the presence various C. scindens 
strains possibly due to the bacteriocins produced by the C. scindens strains.  In sum, these 
observations indicate that phenotypic and genetic variation of C. difficile strains used to 
study the inhibitory effects of C. scindens may significantly influence the results.  
 
Conclusion 
Hence, the data presented here indicate that C. scindens effectively inhibits C. difficile in 
both batch and continuous culture.  Growth inhibition of C. difficile by some C. scindens 
strains proceed by a bile acid dependent mechanism, as evidenced by the dose dependent 
inhibition by CA in the presence of some C. scindens strains.  All C. scindens tested also 
inhibit C. difficile in a bile acid independent manner, as indicated by the observation 
spentC. scindens culture supernatant inhibited C. difficile.   Since antibiotic treatment often 
causes recurrence of C. difficile infection, identifying resident members of the commensal 
gut microbiota that inhibit C. difficile growth and provide colonization resistance has been 
proposed as a means of developing defined bacteriotherapy against C. difficile infection. 
C. scindens is a member of gut commensal that has shown high effectiveness in inhibiting 
C. difficile. However, focusing on using secondary bile acid production of C. scindens 
alone as a means of developing bacteriotherapy may have long-term health complications 
for patients. For example, high activity bile acid dehydroxylating strains can induce 
colorectal cancer by producing DCA in colon which induce colonal stem cells in colonic 





inhibit C. difficile through bile-independent mechanisms could be an effective means of 
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OVERALL CONCLUSION AND FUTURE DIRECTION 
 
This study examined the Prevotella dominated human gut microbiota utilizing culturomics 
and addressed questions regarding individual bacteria colonization resistance against C. 
difficile in vitro. According to results from this study, the majority of the Prevotella 
dominated gut microbiota confer colonization resistance against C. difficile. However, a 
detailed mechanism of resistance against the pathogen by each species needs further 
investigation. Additionally, using the combinatorial assembly technique, we found that the 
minimum set of bacteria required as a community to provide protection against C. difficile 
is twelve. With detailed phenotypic characterization of the individual species in terms of 
substrate utilization, short chain fatty acid production, genetic traits and inhibition against 
C. difficile presented in this study, it is now possible to undertake the ecological community 
assembly, resilience and colonization resistance studies using a Prevotella dominated 
microbial community. These studies will help us develop the microbial therapeutics against 
multidrug resistance gut pathogens such as C. difficile and understand chronic 
inflammatory gut diseases such as Crohn’s disease and inflammatory bowel disease. 
 
The ability to isolate two novel species from a Prevotella dominated microbiota on a single 
medium in this culturomics study suggests this microbiota enterotype is not well defined.  
Also, the effect of prebiotic substrates such as rice bran and quercetin on this microbiota 
includes the potential benefits of reduced Enterobacteriaceae by enhancing propionate 
production. However, further culturing and isolation of the microbes enriched in the 
combined rice bran and quercetin substrate is warranted due to their potential as synbiotics 






The hypothesis that C. difficile is inhibited by bile dependent mechanisms of C. scindens 
is supported by this study. However, strain wise variations are apparent when genetically 
and phenotypically analyzing for inhibition against C. difficile. Additionally, some strains 
of C. scindens were also able to inhibit C. difficile even in the absence of bile. Thus, use of 
non-bile converting, but C. difficile inhibiting, C. scindens strains would not only reduce 
the negative impact of microbe mediated high deoxycholate production in the gut but also 
provide colonization resistance against C. difficile.  
 
With interpersonal variation, the key question of how the gut microbiota assembles and 
how it affects colonization resistance against gut pathogens remains poorly understood.  
Even though our study provides insights into species that inhibit C. difficile in vitro, further 
in vivo studies are required to explore their full potential as a community. This knowledge 
will help develop biotherapeutics against gut diseases.  
